Antisense oligonucleotide depletion of *CCDC146* is a broad-spectrum therapeutic strategy for ALS

Sai Zhang[1,2,15,†], Tobias Moll[3,15], Jasper Rubin-Sigler[4,15], Sharon Tu[4], Shuya Li[5], Enming Yuan[6], Menghui Liu[1], Marriane King[3], Elham Alhathli[3], Connie Treanor[3], Alison Twelvetrees[3], Marcel Weinreich[3], Sam Bonsall[3], Calum Harvey[3], Sarah Gornall[3], Allan Shaw[3], Johanna Ganssauge[7], Akshay Bhinge[7], Cleide Dos Santos Souza[3], Laura Ferraiuolo[3], Eran Hornstein[8], Ophir Shalem[9], Anna Avila[3], Tatyana Shelkovnikova[3], Charlotte H. van Dijk[10], Ilia S. Timpanaro[10], Kevin P. Kenna[10], Jianyang Zeng[5], Philip van Damme[11], Philip S. Tsao[12,13], Pamela J. Shaw[3,14], Justin K. Ichida[4], Johnathan Cooper-Knock[3,14,†], Michael P. Snyder[2,†]

[1]Department of Epidemiology, University of Florida, Gainesville, FL, USA

[2]Department of Genetics, Center for Genomics and Personalized Medicine, Stanford University School of Medicine, Stanford, CA, USA

[3]Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK

[4]Department of Stem Cell Biology and Regenerative Medicine, Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research, University of Southern California, Los Angeles, CA, USA

[5]School of Engineering, Research Center for Industries of the Future, Westlake University, Hangzhou, Zhejiang, China

[6]Institute for Interdisciplinary Information Sciences, Tsinghua University, Beijing, China

[7]Living Systems Institute, University of Exeter, Exeter, UK

[8]Departments of Molecular Genetics and Molecular Neuroscience, Weizmann Institute of Science, Rehovot, Israel

[9]Department of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

[10]Department of Neurology, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, The Netherlands

[11]Neurology Department, University of Leuven (KU Leuven), Belgium

[12]VA Palo Alto Healthcare System, Palo Alto, CA, USA

[13]Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA

[14]NIHR Sheffield Biomedical Research Centre, Sheffield, UK

[15]These authors contributed equally: Sai Zhang, Tobias Moll, and Jasper Rubin-Sigler

[†]Correspondence: sai.zhang@ufl.edu; j.cooper-knock@sheffield.ac.uk; mpsnyder@stanford.edu

Abstract

Amyotrophic lateral sclerosis (ALS) is a heritable and incurable disease defined by the degeneration of motor neurons (MNs), yet the genetics of ALS remain partially understood. Using a genomic deep learning-powered whole-genome analysis of 6,715 ALS patients, we identify four rare noncoding variants associated with patient survival, including chr7:76,009,472:C>T which is linked to a 70.6% reduction in survival. Genetic editing of this variant into iPSC-derived MNs increases *CCDC146* expression and exacerbates ALS-specific phenotypes including TDP-43 mislocalization. We reveal that CCDC146 was located within the basal body of primary cilia in human MNs, and that cilia structure and function is impaired by *CCDC146* overexpression but is restored by its depletion. Suppressing *CCDC146* using an antisense oligonucleotide (ASO) completely rescues ALS-specific survival defects in neurons derived from both sporadic and familial patients, and it extends survival and reverses TDP-43 pathology in an aggressive ALS mouse model. Taken together, CCDC146 is a new modifier of ALS survival that acts via the primary cilia of MNs. ASO targeting of *CCDC146* is a potential therapeutic approach for both sporadic and genetic forms of ALS, particularly because congenital absence of CCDC146 is well tolerated.

Introduction

Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease[1] characterized by the progressive loss of motor neurons (MNs), ultimately leading to respiratory failure and death. ALS survival is markedly heterogeneous: the median survival is between 20 and 48 months, but 10-20% of ALS patients live longer than 10 years[2]. This heterogeneity persists even between patients who share the same monogenic risk factor[3]. A wide range of genetic variations and genes have been associated with ALS risk[4], but a lack of understanding of genetic factors influencing ALS progression is hindering the development of therapies to prolong patient survival.

Conventional genetic analyses, such as genome-wide association studies (GWAS) and rare variant association studies (RVAS) are likely to be underpowered because of limited functional characterization of genetic variants[5,6]. This limitation is pronounced for noncoding variants, which comprise the majority of human genetic material and complex disease heritability[7]. Understanding the biological function of noncoding variants requires specific cellular context because of their involvement in the transcriptional regulation that defines cell identity[8]. Moreover, *rare* variants pose additional challenges in traditional studies of variant function, such as the expression quantitative trait locus (eQTL) analysis[9,10], which rely on prevalent cohort-level evidence. Recent advances in sequence-to-function (seq2func) deep learning models[11–16], also known as genomic deep learning models, provide a powerful alternative method to predict at high-resolution the functional effects of noncoding variants and bypassing the requirement for individual-level data.

In this study, we developed a gDL-powered genetic analysis framework (**Fig. 1**) and performed thus-far the largest (n = 6,715) rare variant analysis for ALS survival, with a focus on the noncoding genetic variants with a functional effect in human MNs. We discovered four novel rare noncoding variants that are associated with an average reduction in ALS survival of more than 50%. We introduced the top scored variant chr7:76,009,472:C>T (where score indicates the probability of an effect on gene expression within MN) into MNs derived from an ALS patient. We confirmed an effect of chr7:76,009,472:C>T on *CCDC146* expression, and an exacerbation of phenotypes associated with ALS including neuronal survival, dendritic regression, TDP-43 localization, and disruption of primary cilia structure and function. Depletion of *CCDC146 in vitro* using an antisense oligonucleotide (ASO) rescued ALS-specific survival deficits in patient-derived neurons, irrespective of the genetic background or of baseline *CCDC146* expression, and without significant toxicity. ASO targeting of murine *Ccdc146* extended survival by over 50% in an aggressive ALS mouse model caused by TDP-43 mislocalization[17]. Indeed the ASO reversed TDP-43 mislocalization and prevented MN loss in the mouse. We localized CCDC146 within the basal body of primary cilia[18] of MNs and

discovered that the structure and function of primary cilia is inversely proportional to CCDC146
expression. Cilia dysfunction has been associated with ALS[19], but our work positions
CCDC146 and MN cilia as a therapeutic target with relevance across the spectrum of ALS
patients.

Results

Overview of the study design

We developed a functional genomics-informed genetic analysis pipeline (**Fig. 1**) to improve
discovery power and interpretability. Briefly, we first predicted the functional impacts of
noncoding variants on gene regulation in human MNs utilizing a gDL. Functional variants were
then mapped to their target genes based on the enhancer-promoter (E-P) interactions
constructed within MNs. Informed by these variant-to-gene maps, a gene burden-based
survival analysis was performed using 6,025 high-quality ALS genomes (out of 6,715
genomes), and pinpointing survival-associated rare variants and corresponding genes. Next,
we measured the effect of the top variant chr7:76,009,472:C>T, and changes in expression of
its target gene *CCDC146,* in iPSC-derived MNs to determine the underlying biology. Finally,
we designed ASOs targeting *CCDC146* to test whether CCDC146 depletion can rescue
disease-associated survival defects across different ALS genetic backgrounds, both *in vitro*
and i*n vivo*. This framework is generic and can be broadly applied to study rare variant genetics
of other complex diseases.

Constructing the regulome and predicting noncoding variant effects in human motor
neurons

To characterize the transcriptional regulation in human motor neurons, we mapped MN E-P
interactions by applying the activity-by-contact (ABC) model[20] (**Supplementary Fig. 1A**) to
the transcriptomic (RNA-seq) and epigenomic (ATAC-seq, H3K27ac ChIP-seq, and Hi-C)
profiling data of iPSC-derived MNs (iMN) derived from neurologically normal donors[21]
(**Supplementary Fig. 1B** and **1C**, **Supplementary Table 1**, **Supplementary Results**;
Methods). A large proportion of MN E-P links (89.0%) were cell-type-specific
(**Supplementary Fig. 1D**), and were relatively enriched with long-range interactions
(**Supplementary Fig. 1E**, **Supplementary Results**). As expected, transcription factors (TFs)
and genes involved in MN E-P links were enriched with biological pathways known to be critical
for MN function (**Supplementary Fig. 1F-1H** and **2A**, **Supplementary Results**).
Next, we sought to examine the function of noncoding variants specifically within MNs.
The activity of epigenomic features, such as chromatin accessibility and histone modifications,
varies widely across cell types and contexts, yet much of this regulation is encoded in the

underlying DNA sequence[11,12,14]. To learn this epigenome grammar in MNs, we developed a

genomic deep learning model[12,22], named NeuroNet, to predict chromatin accessibility and key

histone marks (H3K27ac, H3K4me1, and H3K4me3) in iMNs directly from the reference DNA

sequence (**Fig. 2A**; **Methods**). After training (**Methods**), NeuroNet accurately predicted these

epigenomic features, achieving a mean area under receiver operating characteristic curve

(AUROC) of 0.851 (SD = 0.10; **Fig. 2B**) and a mean area under precision-recall curve

(AUPRC) of 0.853 (SD = 0.063; **Fig. 2C**).

We then used NeuroNet to characterize the functional effects of noncoding variants in

MNs by querying the difference in predicted epigenomic features between reference and

alternative alleles (**Fig. 2A**; **Methods**). Differing from traditional approaches in modeling

variant effects[23], this *in-silico* strategy requires no individual-level data, which greatly increases

its flexibility and generalizability. NeuroNet outputs a score that defines the probability of a

specific variant altering a given epigenomic feature. To benchmark our variant effect

prediction, we compared NeuroNet predictions with those of DeepSEA[12], another deep

learning model which has been used to predict 2,002 epigenomic features in various tissues

and cell types. As expected, NeuroNet and DeepSEA predictions aligned well in neuron- and

brain-related tissues and cell types compared to other cell-types (H3K4me1: $P = 2.4 \times 10^{-5}$;

H3K4me3: $P = 4.5 \times 10^{-3}$, two-sided Fisher's exact test; **Fig. 2D** and **Supplementary Fig. 2B**).

The alignment was marginally significant for H3K27ac ($P = 0.059$, two-sided Fisher's exact

test; **Supplementary Fig. 2C**), but not significant for chromatin accessibility ($P > 0.05$, two-

sided Fisher's exact test; **Supplementary Fig. 2D**), probability due to the limited number ($n =$

3) of neurons and brains profiled by the DNase I hypersensitive sites sequencing (DNase-

seq). In ongoing analyses, to integrate information from all epigenomic features, we used the

maximum of all four variant-specific scores to derive the final NeuroNet variant score.

NeuroNet is designed to capture functional consequences of noncoding variants

including, but not limited to, TF binding disruption. To aid the biological interpretation of

NeuroNet predictions, we examined the overlap between NeuroNet-prioritized variants and

variants previously associated with changes in TF binding[24]. We then used this association to

determine which NeuroNet score should be used as a 'cutoff' to assign 'functional' noncoding

variants. Specifically, we split NeuroNet prediction scores into percentiles and examined which

cutoff produced the strongest enrichment with variants that disrupt TF binding[24] (**Methods**).

Variants with higher NeuroNet scores were more enriched with TF-binding-disrupting variants

(**Fig. 2E**). This demonstrates that NeuroNet has captured known TF biology, despite the fact

that TF motifs were *not* included in model training. The strongest enrichment with disruption

to known TF binding motifs was achieved at the 95% cutoff (NeuroNet score ≈ 0.06; $P = 5.5 \times$

10^{-4}, *t*-statistics = 3.46, two-sided *t*-test; **Fig. 2E**). Accordingly, we classified variants with a

NeuroNet score > 0.06 as 'functional' within MN in the remainder of our analyses.

To further examine the functional implication of NeuroNet prediction, we assessed the

distribution of prioritized variants across the genome. Notably, we found that MN cis-regularoty

elements (CREs), including promoters and enhancers, were enriched with variants prioritized

by NeuroNet (odds ratio [OR] > 1.0, two-sided Fisher's exact test; **Fig. 2F**; **Methods**). As in

our TF binding site analysis, this enrichment was positively correlated with the NeuroNet score

in all features, and peak enrichment was obtained at the 95% cutoff threshold (**Fig. 2F**).

Finally, we benchmarked our variant effect prediction against multiple widely-used

methods, including GERP++[25], GWAVA[26], CADD[27], LINSIGHT[28], and DeepSEA[12]. By

following the suggested cutoffs to define functional or deleterious variants for different

approaches, we observed that NeuroNet-defined functional variants were enriched with

functional or deleterious variants prioritized by other methods (*P* < 0.05, OR > 1.0, two-sided

Fisher's exact test; **Fig. 2G**; **Methods**). The strongest enrichment was obtained for DeepSEA,

probably because the model design is most similar to NeuroNet.

NeuroNet-powered rare variant analysis for ALS survival

We sought to integrate NeuroNet prediction with ALS whole-genome sequencing (WGS) data

to identify rare noncoding variants that impact ALS risk or survival via disrupting transcriptional

regulation in MNs.

We performed variant-level and sample-level quality controls (QCs) for 9,600 whole

genomes generated in the Project MinE[29] (Data Freeze 2), resulting in an analysis-ready

cohort encompassing 6,025 ALS patients and 2,264 controls (**Methods**). Next, using

NeuroNet scores, we identified functional noncoding rare variants (allele frequency [AF] <

0.5% within gnomAD v2.1 non-Finnish European [NFE] samples, allele count [AC] ≥ 3 in the

analysis cohort, and NeuroNet score > 0.06) located within MN CREs. We mapped these

variants to their target genes based on the ABC-predicted E-P links. A gene-level rare variant

burden profile (i.e., the number of variants mapped to each gene) was then constructed for

each individual in the QC'ed cohort, ready for downstream genetic association analysis.

We first studied the genetics of ALS risk. We conducted a rare variant burden risk

analysis (ALS patients versus healthy controls) using SKAT-O[30,31] to quantify the burden of

NeuroNet-prioritised variants (**Methods**), with covariates including age, sex, age^2, sex x age,

sequencing platform, and the first 20 principal components to adjust for known confounders.

No gene was significantly associated with ALS risk after multiple testing correction, suggesting
an underpowered analysis (**Supplementary Table 2**). However, a number of genes that have
been linked to ALS risk achieved nominal significance, such as *KIF5A*[32,33] (P = 0.016) and
NEAT1[34] (P = 0.033).

Next, we performed a rare variant burden survival analysis using the Cox proportional-
hazards (PH) model to measure the effect of NeuroNet-prioritised variants (**Methods**). We
included 26 covariates: age, sex, age^2, sex x age, sequencing platform, *C9orf72* status, and
the first 20 principal components, to adjust for known confounders. Noncoding rare variant
burden was significantly associated with ALS survival for seven genes after Bonferroni multiple
testing correction (adjusted P < 0.05; **Fig. 3A** and **3B**, **Supplementary Table 3**), for which no
inflation was observed (λ = 0.99). The mean survival time for the carriers of these rare variants
ranges from 0.99 to 2.46 years, which is 2.79 to 1.32 years shorter than that of the overall
cohort (**Fig. 3C**).

Four variants were linked to three gene sets: chr7:76,009,472:C>T resides within an
enhancer linked to *CCDC146*, *FAM185BP*, *FGL2*, and *UPK3B* (**Fig. 3D**)*;*
chr14:102,782,854:G>A and chr14:102,786,108:G>T are located within an enhancer of
ZNF839 (**Fig. 3E**); chr2:51,259,489:G>C is within the promoter of *NRXN1* (**Supplementary**
Fig. 3A). As a benchmark, we performed a standard rare variant burden survival analysis
without variant prioritization using NeuroNet (**Methods**), but no gene passed multiple testing
correction (**Supplementary Fig. 3B** and **Supplementary Table 4**). These results
demonstrate the superiority of our deep learning-based framework in enhancing discovery
power and biological interpretation.

Lastly, we were interested in the overlap of rare variant associations between ALS
survival and risk. We examined this by testing the enrichment of survival-associated genes
within risk-associated genes under different P-value cutoffs. Notably, we observed significant
gene overlaps across a spectrum of P-value cutoffs (P < 0.05, two-sided Fisher's exact test;
Supplementary Fig. 3C), suggesting an overlapping genetic architecture underlying these
two ALS phenotypes within noncoding genomic regions.

Reproducing chr7:76,009,472:C>T within iMNs alters CCDC146 expression and
exacerbates ALS-associated phenotypes

The noncoding variant chr7:76,009,472:C>T achieved the highest NeuroNet score amongst
noncoding variants associated with ALS survival (**Fig. 3B**). This variant was linked to four
candidate target genes based on predicted E-P links (**Fig. 3D**). To experimentally verify our
prediction and determine the regulatory target of chr7:76,009,472:C>T, we utilized CRISPR-
Cas9 to reproduce this variant in iPSCs derived from an ALS patient caused by a G4C2-repeat
expansion within *C9orf72* (**Fig 4A**; **Methods**), where the unedited cells served as an isogenic

control. Of note, we observed extremely rapid disease progression in a patient who carried
both a *C9orf72* expansion and chr7:76,009,472:C>T in the Project MinE cohort
(**Supplementary Table 5**).

We first examined whether chr7:76,009,472:C>T altered the expression of candidate
target genes implicated by predicted E-P links. To achieve this, we differentiated edited iPSCs
carrying chr7:76,009,472:C>T, as well as isogenic control iPSCs, into mature MNs using our
published small molecule protocol[21] (**Supplementary Fig. 4A**; **Methods**). The ABC model
predicted an E-P link for four genes: *CCDC146, FAM185BP, FGL2,* and *UPK3B*. Study of
human tissue revealed that UPK3B is almost exclusively expressed in urothelium[35], and
therefore we excluded this gene from further study. We extracted RNA from mature iMNs and
measured the expression levels for *CCDC146, FAM185BP,* and *FGL2* (**Methods**). Expression
of *CCDC146* was significantly elevated in the presence of chr7:76,009,472:C>T compared to
isogenic control iMNs (P = 5.6 x 10^{-3}, fold change [FC] = 1.35, two-sided *t*-test; **Fig. 4B**), but
FAM185BP, and *FGL2* were not differentially expressed.

Next, we sought to determine the effect of chr7:76,009,472:C>T on ALS-associated
phenotypes within iMNs. Our genetic analysis suggested that chr7:76,009,472:C>T increased
the rate of ALS progression, resulting in a more severe phenotype; therefore we hypothesized
that chr7:76,009,472:C>T would increase the severity of ALS-associated phenotypes in iMNs
compared to isogenic control iMNs. For an additional comparison, we also included iMNs from
an age- and sex-matched neurologically normal individual.

ALS is associated with a number of MN molecular phenotypes, including increased
cell death[36], reduced neurite outgrowth[37,38], and TDP-43 mislocalization[39]. We took advantage
of this battery of phenotypes to assess the effect of chr7:76,009,472:C>T on ALS severity *in*
vitro. iMNs were placed in culture and monitored continuously for 12 days (**Methods**). We
measured cell survival and neurite growth at 8 hour intervals. Notably, compared to isogenic
control iMNs, the presence of chr7:76,009,472:C>T was associated with a reduction in both
neurite length (P < 0.05, two-sided *t*-test; **Fig. 4C**) and the number of neurite branch points
(**Supplementary Fig. 4B**), and with increased neuron death (**Supplementary Fig. 4C**). iMNs
carrying chr7:76,009,472:C>T had a significantly higher burden of TDP-43 mislocalization at
the end stage (P = 0.024, two-sided *t*-test; **Fig. 4D** and **4E**; **Methods**), compared to isogenic
control iMNs.

Previous literature suggests that CCDC146 is located within the basal body of primary
cilia[18]. We confirmed that this is also the case within iMNs (**Supplementary Fig. 4D**;
Methods). Moreover, in iMNs that carried chr7:76,009,472:C>T with elevated *CCDC146*
expression, the length of primary cilia was reduced compared to the isogenic control iMNs (P
= 0.04, paired *t*-test; **Fig. 4F** and **4G**; **Methods**). Primary cilia function is related to CRABP1
expression and hence the maintenance of neuromuscular junctions (NMJs) between MNs and

their target muscles[40]. NMJ loss is a key phenotype of ALS[41] and reduced CRABP1 has been
linked to ALS[19]. Immunoblotting for CRABP1 revealed that in iMNs carrying
chr7:76,009,472:C>T, CRABP1 expression was reduced compared to the isogenic control
iMNs ($P = 0.03$, paired t-test; **Fig 4H** and **4I**; **Methods**). Interestingly, ALS-associated Q331K-
TARDBP mutations, which disrupt function of TDP-43, have been associated with large
downregulation of CRABP1 mRNA[42] suggesting that the link between ciliary function and
CRABP1 expression may be mediated via TDP-43 dysfunction.

We have shown that CCDC146 is located within the basal body of primary cilia and
that *CCDC146* levels have an effect on cilia structure and function. CCDC146 is a microtubule-
associated protein and cilia are formed from microtubules. Based on this, we further examined
microtubule dynamics. EB3 is a well-established regulator of primary cilium biogenesis,
facilitating the anchoring of microtubule minus-ends at the basal body and promoting vesicular
trafficking to the ciliary base[43,44]; EB3 depletion has been shown to reduce primary cilium
length[43]. Interestingly, we identified a significant reduction in EB3 velocity in
chr7:76,009,472:C>T-iMNs with increased *CCDC146* expression (FC = 0.8, $P = 0.039$,
unpaired t-test; **Fig. 4J** and **4K**; **Methods**), suggesting that the disrupted microtubule
dynamics is the link between *CCDC146* and cilia structure and function.

ASO suppression of CCDC146 corrects cilia dysfunction and rescues ALS-associated
survival deficits in patient-derived neurons

We have linked chr7:76,009,472:C>T to elevated expression of *CCDC146* and to ALS-
associated molecular phenotypes in iMNs, including TDP-43 mislocalization and cilia
dysfunction. To further test whether the expression change of *CCDC146* is the key driver of
this toxicity, we synthesized an antisense oligonucleotide (ASO) targeting *CCDC146* mRNA
for degradation.

We have established a survival readout for iPSC-derived neurons (iNs) whereby
neurons derived from patients display an increased sensitivity to glutamate-induced
excitotoxicity[36,45] (**Fig. 5A**; **Methods**). This reflects long standing observations regarding
glutamate toxicity in ALS[46–48]. We have also established this readout in a 3D spheroid format
(3D-iN) to enable prolonged culturing without primary glial cells[45,48] (**Fig. 5A**; **Methods**). In our
experiment, we treated 3D-iNs derived from multiple patients, including four healthy controls,
four ALS patients carrying an *C9orf72* G4C2-repeat expansion, two ALS patients carrying
ALS-associated mutations within TARDBP, and five sporadic ALS (sALS) patients
(**Supplementary Table 6**). 3D-iNs were exposed to either *CCDC146* ASO or a scrambled
control ASO, followed by longitudinal tracking (**Fig. 5A**; **Methods**). First, we confirmed the
reduction in *CCDC146* mRNA level within 3D-iNs treated with the *CCDC146* ASO compared
to the scrambled ASO (36.9% reduction, $P = 0.031$, two-sided t-test; **Fig. 5B**; **Methods**).

Notably, we observed that the survival defect was completely rescued by *CCDC146*
suppression compared to the scrambled ASO ($P < 0.05$, two-sided *t*-test; **Fig. 5C-E** and
Supplementary Fig. 5A). The result persisted across all of the different genetic backgrounds
tested in our experiment (11 patient lines in total; **Fig. 5C-D** and **Supplementary Fig. 5A**).
Moreover, there was no evidence of toxicity mediated by the *CCDC146* ASO in control 3D-iNs
($P > 0.05$, two-sided *t*-test; **Fig. 5D** and **Supplementary Fig. 5A** and **5B**). Indeed, loss-of-
function (LoF) of CCDC146 has been shown to be well tolerated in humans[18]. Of note, none
of the experimentally-tested patient-derived 3D-iN lines exhibited elevated *CCDC146*
expression at baseline (**Supplementary Fig. 5C**). Together, these results demonstrate that
CCDC146 suppression may be a broadly applicable therapeutic strategy for different forms of
ALS.

Next, we sought to determine whether ASO suppression of *CCDC146* reverses deficits
in primary cilia structure and function (**Fig. 4G** and **4H**) which were associated with
chr7:76,009,472:C>T and increased expression of *CCDC146*. We treated iMNs derived from
a patient carrying a *C9orf72* G4C2-repeat expansion with *CCDC146* ASO and measured
primary cilia length and CRABP1 expression after 72 hours (**Methods**). Cilia length was
significantly increased after *CCDC146* ASO treatment compared to untreated iMNs and to
treatment with a scrambled ASO ($P = 0.03$, one-way ANOVA; **Fig. 5F** and **Supplementary**
Fig. 5D). Similarly, CRABP1 expression was increased after treatment with *CCDC146* ASO
compared to scrambled ASO ($P = 0.01$, paired *t*-test; **Fig. 5G** and **5H**).

We conclude that *CCDC146* suppression rescues ALS-associated survival defects *in*
vitro and reverses deficits in cilia structure and function, suggesting that ciliary function is the
mechanism by which *CCDC146* modifies neuronal survival.

ASO suppression of murine Ccdc146 rescues motor phenotypes and survival defects associated with TDP-43 mislocalization

Depletion of human *CCDC146* corrected survival defects in ALS patient-derived neurons
irrespective of genetic background and including sporadic ALS. The majority of ALS is
associated with TDP-43 mislocalization[41], and therefore we hypothesised that *CCDC146*
depletion may be effective in an *in vivo* model of ALS caused by TDP-43 mislocalization.
Moreover, in iMNs the elevated *CCDC146* expression was associated with an increase in
TDP-43 mislocalization, suggesting that reducing *CCDC146* expression may reverse this
aberration. To test these hypotheses, we utilized an aggressive juvenile mouse model
(TAR4/4 mouse) of ALS caused by overexpression of human TDP-43 which manifests with
mislocalization of human and murine tdp-43[17] (**Fig. 6A**). This model has been previously used
to develop therapeutic strategies for ALS[49].

We generated an ASO against murine *Ccdc146* which successfully depleted *Ccdc146*
expression when injected intracerebroventricular (IVC) at D1 (P = 6.14 x 10^{-3}, two-sided *t*-test;
Fig. 6B; **Methods**). Notably, the *Ccdc146* ASO mitigated motor phenotypes compared to a
scrambled ASO and the difference increased over time (**Fig. 6C**); at D22 the differences were
significant for all measures (n > 30 in each group; gait impairment score: P = 2.7 x 10^{-4}; tremor
score: P = 2.2 x 10^{-4}; kyphosis score: P = 2.1 x 10^{-4}, two-sided *t*-test; **Fig. 6C**; **Methods**).
Moreover, survival was significantly prolonged in mice treated with the *Ccdc146* ASO (n = 55,
36% increase in median survival time, P = 5.5 x 10^{-6}, Cox regression; **Fig. 6D**; **Methods**),
compared to mice treated with the scrambled ASO. To determine whether the *Ccdc146* ASO
acts via reversal of MN toxicity, we performed MN counts in wild type and TAR4/4 mice treated
with *Ccdc146* or scrambled ASO. Treatment with *Ccdc146* ASO significantly increased the
average number of MNs at D22 (P = 1.6 x 10^{-4}, two-sided *t*-test; n > 10 biological replicates, n
= 6 fields-of-view (FOV) per mouse; **Fig. 6E** and **6F**). Indeed at D22, MN counts in *Ccdc146*
ASO-treated TAR4/4 mice were equivalent to wild type animals (**Fig. 6E**). Finally, we sought
to examine the distribution of murine TDP-43 within MNs using immunohistochemistry
(**Methods**). The *Ccdc146* ASO significantly increased the nuclear:cytoplasmic ratio of murine
TDP-43 within MNs at D22 compared to the scrambled ASO (P = 1.76 x 10^{-4}, two-sided *t*-test;
Fig. 6G and **6H**), exhibiting an almost complete rescue of TDP-43 mislocalization when
compared to the wild type mice (P > 0.05, two-sided *t*-test; **Fig. 6G** and **6H**).
We conclude that ASO suppression of *CCDC146* is an effective therapeutic strategy
in vivo, and that this activity is upstream of TDP-43 mislocalization which is the defining
pathology of ALS[39].

Discussion

We have designed ASOs targeting *CCDC146* which ameliorate ALS-associated phenotypes,
including survival and TDP-43 mislocalization both *in vitro* and *in vivo*. We achieved this by
starting with a hypothesis-free *in-silico* screen for genetic modifiers of ALS survival. Distinct
from previous works, our genetic screen was built upon a deep learning-based variant
interpretation framework that makes MN-specific functional effect predictions for an
exhaustive set of noncoding variants. Our model, named NeuroNet, was trained to predict
various MN epigenomic features (e.g., chromatin accessibility and histone modification) from
DNA sequence. This enables the model to make functional predictions for unseen genetic
variants irrespective of allele frequency. Deep learning-based seq2func modeling has been
widely adopted to examine the cell-type-specificity of regulatory genome function and genome
variation[11–16,22,50], and here we demonstrated its success in identifying potential therapeutic
targets for ALS. Conventional approaches for investigating variant effects, such as the
expression and chromatin accessibility quantitative trait loci (eQTL and caQTL) analyses,

require matched individual genotype and transcriptomic/epigenomic profiling data, which is
typically underpowered for the study of rare or ultra-rare variants.

Combining NeuroNet predictions of variant effects on the epigenome, together with
enhancer-promoter links, enabled us to build a variant-to-gene (V2G) map within MNs. The
result is a gene-resolved prediction of noncoding variant function. Based on this V2G, we have
conducted large-scale rare variant burden tests for both ALS risk and survival. Although the
risk analysis was underpowered due to the paucity of control samples, a NeuroNet-enabled
survival analysis succeeded whereas a traditional analysis was still underpowered. This
demonstrates the benefit of incorporating functional information into a genetic analysis.

We have identified four noncoding variants linked to ALS survival, and they were
predicted to modulate the expression of three protein-coding genes: *ZNF839*, *NRXN1*, and
CCDC146. Interestingly, although we did not identify any genome-wide significant genes
associated with ALS risk, we did note a significant overlap between nominally significant risk-
and survival-associated genes. This is consistent with known genetic variants which affect
both ALS risk and survival including noncoding variants associated with *UNC13A*[51] and
C9orf72[3], and provides evidence for the overlapping genetic architecture of ALS risk and
survival within the noncoding genome.

We reproduced the top hit chr7:76,009,472:C>T in iMNs carrying an ALS-associated
G4C2 expansion within *C9orf72*, and verfied its regulation of *CCDC146* expression. We
showed that chr7:76,009,472:C>T exacerbated ALS-associated phenotypes in iMNs,
including reduced MN survival compared to isogenic control neurons. Moreover, using an ASO
to reduce *CCDC146* expression completely rescued ALS-associated survival defects in iMNs,
irrespective of genetic background and without significant toxicity, and also irrespective of the
baseline *CCDC146* expression. Similarly, we observed a dramatic survival benefit in an
aggressive mouse model of ALS caused by mislocalization of nuclear TDP-43[17], which is the
key molecular pathology underlying >98% of ALS[39]. We note that a different ASO has recently
been approved for treatment of ALS patients carrying a pathogenic mutation within SOD1[52].
Unlike that treatment - Tofersen - our data suggest an ASO targeting *CCDC146* could be
administered to broad forms of ALS and not limited to a specific genetic subtype.

CCDC146 is a microtubule associated protein (MAP) and localized to sperm flagella
and to primary cilia in particular. Biallelic variants in *CCDC146* have been associated with
reduced sperm viability and non-syndromic male infertility in both mice and humans[18]. Flagella
are functionally mirrored by cilia and it is notable that primary cilia dyskinesia has been
associated with ALS[19,53,54]. Here, we have determined that CCDC146 is localized to primary
cilia in human MNs, in a similar manner to *C21ORF2/CFAP410*[19] which is an ALS risk gene[55]
and is important for cilia assembly. Our data suggest that this may be because CCDC146 is
a modifier of microtubule dynamics, and cilia are microtubule structures. Primary cilia occur

one per cell in neurons and extend into the extracellular space where they can transduce intercellular signals via G-protein coupled receptors. Unlike in sperm cells, neuronal cilia are non-motile structures with an important role in sensing extracellular signals and in transduction of *sonic hedgehog* (shh) signalling. Elevated *CCDC146* causes shortened primary cilia which would be expected to impair intraflagellar transport (IFT)[19]. IFT is the process by which structural components are selected and positioned for the assembly and maintenance of cilia structure; indeed IFT occurs continuously in two directions towards and away from the tip of each cilium and occurs in proportion to cilium length[56].

We identified loss of CRABP1 in MNs overexpressing *CCDC146* and increase in CRABP1 after *CCDC146* depletion by ASO. CRABP1 is an important protein for NMJ structure and function within MNs. CRABP1 expression is relatively specific to the spinal cord and to MN in particular[40]; indeed CRABP1 knockout mice exhibit an ALS-like phenotype, including MN degeneration[40]. *CRABP1* expression has been linked to ciliary function via shh signalling[57], and we also note reports in the literature of a link between TDP-43 dysfunction and *CRABP1* expression[42]. Indeed, *CRABP1* is implicated in maintenance of NMJ function via *CAMK2B* and *AGRN*[40], both of which are misplaced in the context of TDP-43 dysfunction[58]; this convergence supports the idea that this is a key pathway in driving neuronal toxicity in ALS. We suggest that the positive effect of *CCDC146* on MN health is mediated via modification of ciliary function leading to recovery of TDP-43 mislocalisation and elevation of CRABP1 expression. TDP-43 mislocation is a key driver of >98% of ALS[39,58,59] and so our proposed mechanism would explain why the *CCDC146* ASO appears to be broadly applicable to patient-derived neurons. Here we have provided evidence to link *CCDC146* expression to TDP-43 mislocalization both *in vitro* and *in vivo*. While further research is needed to confirm and clarify the interaction between ciliary function and TDP-43 mislocalization, our work opens a new avenue for understanding the role of primary cilia as a universal driver of MN death in ALS.

It is notable that, aside from a nonsyndromic fertility defect, loss of CCDC146 is well tolerated[18]; this crucial observation suggests that our ASO approach may be viable without significant toxicity. Additionally, this gene is not well conserved[60] (probability of loss of function intolerance (pLI) = 0). CCDC146 is expressed throughout the brain and spinal cord, and particularly within neurons[61] (Human Protein Atlas). Expression of *CCDC146* has been identified specifically in neurons from the human spinal cord[62]. Matching our finding of higher *CCDC146* expression associated with reduced ALS survival, the expression of *CCDC146* is higher in ALS patient spinal cord compared to control cervical spinal cord although, at a bulk level, this difference was not statistically significant[63].

We investigated the potential of targeting CCDC146 through small-molecule drugs. We first searched chemical and patent databases but found no active compounds targeting

CCDC146 and similar proteins (**Methods**). CCDC146 is also classified as a poorly explored target without active small molecules according to the Pharos database[64,65]. Due to the lack of experimentally solved protein structure data, we obtained the AlphaFold-predicted structure of CCDC146[66] (**Supplementary Fig. 6**). The predicted structure mainly consists of coiled coils linked by flexible regions, without ligand binding sites detected on its surface[67] (**Methods**), suggesting that it would be challenging to design small-molecule drugs for this target and underscoring the importance of alternative targeting approaches such as an ASO.

We also sought to validate another gene *ZNF839* in the context of disease progression. In particular, we inspected gene expression in iMNs derived from an independent cohort encompassing 245 ALS patients (www.answerals.org; **Methods**). We measured disease progression using two metrics, including the survival time from symptom onset and the rate of change in ALS Functional Rating Scale in its revised version (ALSFRS-R)[68]. ALSFRS-R is widely used to measure ALS progression[69]. We found that lower expression of *ZNF839* was associated with faster rate of disease progression ($\beta = 0.85$, $P = 5.9 \times 10^{-3}$, multivariable linear regression; **Supplementary Fig. 7A**; **Methods**) and shorter survival time ($\beta = -0.79$, $P = 0.044$, Cox PH regression; **Supplementary Fig 7B**; **Methods**). The expression levels of other genes we identified were not correlated with either the rate of change in the ALSFRS-R or survival, probably because the AnswerALS-based analysis was underpowered.

Given the significant enrichment of European samples in our WGS cohort, a potential limitation of our work is that our conclusions might not be generalizable to other ancestral groups. However, the allele frequencies of all four survival variants are below 1% (the maximum population-level allele frequency is 5.9% obtained for chr14:102,782,854:G>A) across different populations according to the gnomAD whole-genome collection 2.1.1, implicating the ancestral transferability of the effect of our identified variants, although further confirmation is required.

In summary, we have developed a deep learning-powered genetic analysis framework for systematic identification of cell-type-resolved genetic modifiers of ALS survival. Each of the candidate genes we pinpointed represents a potential therapeutic target, but we have demonstrated *in vitro* and *in vivo* that ASO knockdown of *CCDC146* is a safe, broadly applicable and efficacious therapeutic strategy. NeuroNet can be applied to study the genetics of other MN-specific diseases, including spinal muscular atrophy (SMA) and hereditary sensory and motor neuropathy (HSMN). Our analysis framework contributes to a better understanding of ALS genetic architecture, defines a novel therapeutic target for ALS, and provides a generic paradigm for enhancing noncoding genetic analysis of complex human diseases.

Acknowledgments

This work was supported by NIH (CEGS 5P50HG007735 to M.P.S., R01NS131409 and
R01NS097850 to J.K.I.), Wellcome Trust (216596/Z/19/Z to J.C.-K.), NIHR (NF-SI-0617-
10077 to P.J.S.), Motor Neurone Disease (MND) Association (894-791, 899-792 and 913-792
to C.H., S.G., S.Z. and J.C.-K.), John Douglas French Alzheimer's Foundation (to J.K.I.), and
Robert Packard Center for ALS Research (1375407 to S.Z.). We also acknowledge support
from the MND Association Fellowship (2323-799) and the Kingsland Fellowship (to T.M.), the
NIHR Sheffield Biomedical Research Centre (NIHR203321), and the NIHR Sheffield Clinical
Research Facility. We are very grateful to the ALS patients and control subjects who
generously donated biosamples. We acknowledge transcriptomic and clinical data provided
by the AnswerALS Consortium. Figures 1, 2a, 4A, 5A and 6A were created using
BioRender.com.

Author contributions

S.Z., J.C.-K. and M.P.S. conceived and designed the study. S.Z. and E.Y. developed
NeuroNet. S.Z., J.C.-K., T.M. and J. R.-S. performed statistical analyses. T.M. performed all
the experiments for reproducing and characterizing chr7:76,009,472:C>T in iMNs. J. R.-S.,
S.T. and T.M. carried out ASO-related experiments in 3D-iNs, iMNs and mice. S.Z., J.C.-K.,
T.M. and J. R.-S. interpreted the data with assistance from all other authors. The Project MinE
ALS Sequencing Consortium was involved in WGS data acquisition and analysis. S.Z., J.C.-
K. and M.P.S. supervised the work. S.Z., J.C.-K. and M.P.S. wrote the manuscript with
feedback from all other authors.

Competing interests

M.P.S. is a co-founder and the scientific advisory board member of Personalis, Qbio, January,
SensOmics, Filtricine, Akna, Protos, Mirvie, NiMo, Onza, Oralome, Marble Therapeutics and
Iollo. He is also on the scientific advisory board of Danaher, Genapsys, and Jupiter. J.K.I. is a
co-founder and a scientific advisory board member of AcuraStem, Inc. and Modulo Bio, a
scientific advisory board member of Synapticure and Vesalius Therapeutics. J.K.I. is also an
employee of BioMarin Pharmaceutical. The remaining authors declare no competing interests.
We have a patent application related to this work.

Main figure legends

Fig. 1. Schematic of the study design. Leveraging epigenomic and transcriptomic profiling
of iPSC-derived human motor neurons (iMNs), we first identified enhancer-promoter (E-P)
interactions using the Activity-by-Contact (ABC)[20] model (**Panel 1**, top). Next, we developed
a genomic deep learning model[12,14] named NeuroNet to prioritize functional noncoding

variants that could significantly alter MN epigenomes (**Panel 1**, bottom). Using the Project
MinE[29] whole genome sequencing (WGS) data (**Panel 2**), we identified risk variants and genes
modulating ALS survival (**Panel 3**) via the Cox proportional-hazards (PH) model, in which we
collapsed all functional rare noncoding variants (predicted by NeuroNet) to their target genes
(predicted by the ABC model). To validate our discovery, we introduced the top candidate
variant chr7:76,009,472:C>T into patient-derived iMNs using CRISPR-Cas9 (**Panel 4**, left),
and verified its regulatory effects on *CCDC146* expression and ALS-associated phenotypes
(**Panel 4**, right), including cell survival, neurite growth, and TDP-43 mislocalization. Finally, we
designed ASOs suppressing *CCDC146* (**Panel 5**, left). We demonstrated that *CCDC146*
ASOs rescued ALS-associated survival deficits in patient-derived neurons across different
genetic backgrounds, and improved motor phenotypes, survival, and MN loss in an aggressive
ALS mouse model (**Panel 5**, right). iPSC, induced pluripotent stem cell; CRE, cis-regulatory
element; TF, transcription factor; fRV, functional rare variant; ASO, antisense oligonucleotide;
RNase H, Ribonuclease H.

Fig. 2. NeuroNet predicts the noncoding variant effects in MNs. (**A**) Schematics of the
NeuroNet model. (**B-C**) Predictive performance of NeuroNet evaluated based on the receiver
operating characteristic (ROC) curve (**B**) and precision-recall curve (**C**). The area under curve
(AUC) scores were calculated for different epigenomic features and metrics. The dashed gray
line indicates the random prediction. (**D**) Correlation between NeuroNet and DeepSEA
predictions for H3K4me1. *P*-value by two-sided Fisher's exact test. Neuron- and brain-related
tissues and cell types are highlighted. PCC, Pearson correlation coefficient. (**E**) Enrichment of
TFBS-disrupting variants within NeuroNet-prioritized functional variants (various cutoffs
applied). Enrichment was estimated by *t*-statistics. The box plot center line, limits, and
whiskers represent the median, quartiles, and 1.5x interquartile range (IQR), respectively.
TFBS, transcription factor binding site. (**F**) Enrichment of NeuroNet-prioritized functional
variants (various cutoffs applied) within MN CREs. OR is annotated in the solid line and 95%
CI is represented in the colored area. Statistics of the 95% cutoff were highlighted. *P*-value by
two-sided Fisher's exact test. OR, odds ratio; CI, confidence interval. (**G**) Enrichment of
functional or deleterious variants predicted by traditional approaches within NeuroNet-
prioritized functional variants (cutoff = 0.06). *P*-value by two-sided Fisher's exact test. Dot and
error bar indicate OR and 95% CI, respectively. MLE, Mean -log e-value.

Fig. 3. Survival analysis based on rare functional noncoding variants in motor neurons.
(**A**) Quantile-quantile (QQ) plot of burden-based survival analysis. Genes sharing the same
set of variants were collapsed into groups. The dashed red line indicates the significance cutoff
based on the Bonferroni correction. (**B**) Statistics of significant tests. The dot and error bar
represent the Cox model coefficient and SE, respectively. SE, standard error. (**C**) Kaplan-

Meier (KM) estimator plots for significant tests. Carriers for *ZNF839* variants were defined as

individuals having at least one variant from chr14:102,782,854:G>A and

chr14:102,786,108:G>T. (**D-E**) Regulatory relationships between noncoding variants and

target genes for chr7:76,009,472:C>T (**D**) and *ZNF839* (**E**), respectively. Peak signals from

MNs derived from CS14-iPSCs are visualized. Significant genes after Bonferroni correction

(adjusted *P* < 0.05) are highlighted in red. CRE, cis-regulatory element; E-P, enhancer-

promoter.

Fig. 4. Experimental modeling of chr7:76,009,472:C>T in *C9orf72*-ALS iPSC-derived

motor neurons. (**A**) Schematic of CRISPR/Cas9-mediated modeling of chr7:76,009,472:C>T

in *C9orf72*-ALS iPSC-derived motor neurons (iMNs). (**B**) Gene expression levels measured

by q-RT-PCR for three genes linked to the enhancer harboring chr7:76,009,472:C>T (*n* = 3

technical replicates). The bar plot and error bar represent the mean and standard error,

respectively. *P*-value by two-sided *t*-test. ns, not significant; **, *P* < 0.01. (**C**) Quantification of

neurite length (*n* = 3 technical replicates) in an age- and sex-matched normal control, an

isogenic control carrying a G4C2-repeat expansion of *C9orf72*, and edited iMNs, across 12

days of tracking using the Incucyte live-cell analysis system (Sartorius). The dot and error bar

represent the mean and standard error, respectively. *P*-value by two-sided *t*-test. *, *P* < 0.05.

(**D**) Quantification of the proportion of MNs exhibiting mislocalization of nuclear TDP-43 to the

cytoplasm in isogenic control and edited iMNs. The bar plot and error bar represent the mean

and standard error, respectively. *P*-value by two-sided *t*-test. (**E**) Representative images of

TDP-43 staining (yellow) in edited iMNs; nucleus (DAPI, blue) and cytoplasm (MAP2, red)

staining are also shown. MNs with cytoplasmic mislocalization of TDP-43 are shown (top

panels), together with a cytoplasmic inclusion (arrow); for comparison MNs are shown where

TDP-43 is localized to the nucleus (bottom panels). Scale bar 50µM. (**F**) Representative

images of iMNs where primary cilia were demarcated with Arl13b. Scale bar: original images

100µm; magnified inserts 25µm. (**G**) Measurement of length of primary cilia in iMNs carrying

chr7:76,009,472:C>T compared to an isogenic control carrying a *C9orf72* expansion (each

dot is the mean length from a single field of view, *n* = 3 separate motor neuron differentiations).

P-value by two-sided paired *t*-test. (**H**) Measurement of CRABP1 expression in iMNs carrying

chr7:76,009,472:C>T compared to an isogenic control carrying a *C9orf72* expansion (*n* = 4

technical replicates). *P*-value by two-sided paired *t*-test. (**I**) Immunoblotting for CRABP1 across

different conditions, with TUJ1 for normalization. (**J**) Mean velocity of EB3 comets (µm/sec) in

iMN carrying a *C9orf72* expansion with or without chr7:76,009,472:C>T (*n* = 3 technical

replicates; ≥4 axons imaged per condition per replicate). The bar plot and error bar represent

the mean and standard error, respectively. *P*-value by two-sided *t*-test. (**K**) Straightened axon

and representative kymographs depicting distance moved (μm) by EB3 comets over time
(seconds) in iMN carrying a *C9orf72* expansion with or without chr7:76,009,472:C>T.

Fig. 5. Suppression of *CCDC146* in ALS patient-derived neurons via antisense
oligonucleotide (ASO). (**A**) Schematic of our modeling strategy which utilized patient-derived
GFP-labeled iPSC-derived neurons in 3D spheroids (3D-iNs). Longitudinal tracking enables
accurate cell counting to determine survival following a glutamate insult together with a
scrambled ASO or a *CCDC146*-targeting ASO treatment. (**B**) Comparison of gene expression
levels measured by q-RT-PCR between *CCDC146*-targeting ASO and scrambled ASO
treatments. The bar plot and error bar represent the mean and standard error, respectively.
P-value by two-sided *t*-test. *n* = 4 technical replicates per condition. (**C**) Kaplan-Meier (KM)
estimator plots for four patient cell lines. The shaded area represents 95% confidence interval
(CI). *P*-value by log-rank test. C9, *C9orf72*; sALS, sporadic ALS. (**D**) Comparison of hazard
ratio measuring the incidence of neuron loss among different conditions and treatments. The
bar plot and error bar indicate the mean and standard error, respectively. NC, negative control
(scrambled); ctrl, control; C9, *C9orf72*; sALS, sporadic ALS. *P*-value by two-sided *t*-test. ns,
not significant. (**E**) Representative images of 3D-iNs derived from a sporadic ALS patient
treated with the scrambled ASO (top panels) or the *CCDC146*-targeting ASO (bottom panels).
Images were taken from approximately the same location on the plat at Day 0 (left panels)
and Day 8 (right panels), demonstrating neuronal loss which was rescued by *CCDC146*
suppression. Scale bar: 200μm. (**F-G**) Measurement of length of primary cilia (**F**) and CRABP1
expression (**G**) in iMNs after treatment with *CCDC146* ASO compared to a scrambled ASO or
untreated iMNs. The bar plot and error bar represent the mean and standard error,
respectively. *P*-value by two-sided *t*-test. ns, not significant. (**H**) Immunoblotting for CRABP1
across different treatments, with TUJ1 for normalization.

Fig. 6. ASO suppression of *CCDC146 in vivo*. (**A**) Strategy for evaluating the *Ccdc146* ASO
in Thy1::hTDP43Tg/Tg mice[17]. Intracerebroventricular (ICV) injections of the ASO were
performed at postnatal day 1 (D1), with motor phenotype evaluation every two days from
postnatal day 14 (D14). WT, wild type; MN, motor neuron. (**B**) Mouse endogenous *Ccdc146*
gene expression levels measured after treatment with the *Ccdc146* ASO or a scrambled
control ASO at D4 (*n* = 4 technical replicates). The bar plot and error bar represent the mean
and standard error, respectively. *P*-value by two-sided *t*-test. (**C**) Evaluations of gait
impairment, tremor, and kyphosis after treatment with the *Ccdc146* ASO or a scrambled ASO.
The line plot and error bar indicate the mean and standard error, respectively. *P*-value by two-
sided *t*-test. *, <0.05, **, <0.01, ***, <0.001. (**D**) Kaplan-Meier (KM) estimator plot for mouse
survival after treatment with either *Ccdc146* ASO (*n* = 32) or a scrambled control ASO (*n* =
23). The shaded area represents 95% confidence interval (CI). *P*-value by Cox regression. (**E**)

Motor neuron counts in TAR4/4 and wild type mice treated with either *Ccdc146* ASO or a scrambled control ASO. Mice were sacrificed at D22 for histology. The bar plot and error bar represent the mean and standard error, respectively. *P*-value by two-sided *t*-test. WT, wild type; ns, not significant. (**F**) Immunostaining of large TUJ1+ neurons in the ventral horn of TAR4/4 mice treated with a scrambled ASO or *Ccdc146* ASO used to perform motor neuron counts. (**G**) Immunostaining of total TDP-43 in large TUJ1+ neurons in the ventral horn of wild-type and TAR4/4 mice treated with a scrambled ASO or *Ccdc146* ASO. Dotta lines to outline the cell body/nucleus used for quantification. WT, wild type; NC, negative control (scrambled); TAR4/4, Thy1::hTDP43Tg/Tg. (**H**) Nuclear:cytoplasmic TDP-43 ratio at D22 across different treatments. Each data point represents the average TDP-43 nuclear:cytoplasmic ratio for one mouse. The bar plot and error bar indicate the mean and standard error, respectively. *P*-value by two-sided *t*-test. WT, wild type; ns, not significant.

631 **KEY RESOURCES TABLE**

Reagent or Resource	Source	Identifier
Antibodies		
anti-Nestin	Abcam	#ab18102
anti-Pax6	Abcam	#ab5790
anti-Beta III Tubulin	Abcam	#ab18207
anti-HB9	Abcam	#ab221884
anti-Islet 1/2	Abcam	#AB109517
anti-NeuN	Millipore	#MAB377
anti-ChAT	Millipore	#AB144P
anti-SMI-32	Biolegend	#801701
anti-phospho TDP-43 (Ser409)	Affinity Biosciences	#AF7365
anti-TDP-43	Proteintech	#12892-1-AP
anti-MAP2	Proteintech	#17490-1-AP
anti-GFP	Novus Biologicals	#AB_10128178
anti-NFH	Millipore Sigma	#AB_477272
anti-CCDC146	Sigma	#HPA020082
CoraLite® Plus 488-conjugated anti-ARL13B	Proteintech	#CL488-17711
Donkey anti-Mouse IgG Alexa Fluor 488	Thermofisher	#A-21202
Donkey anti-Rabbit IgG Alexa Fluor 568	Thermofisher	#A-10042
Donkey anti-Goat IgG Alexa Fluor 555	Thermofisher	#A-21432
Goat anti-Guinea Pig IgG Alexa Fluor 647	Thermofisher	#A-21450

Donkey anti-Mouse IgG Alexa Fluor 594	Thermofisher	#A-32744
Donkey anti-Rabbit IgG, Alexa Fluor 488	Thermofisher	#A-21206
Donkey anti-Mouse IgG Alexa Fluor 568	Thermofisher	#A-10037
Goat anti-Chicken IgY (H+L) Alexa Fluor Plus 488	Thermofisher	#A-32931
Alexa Fluor 680-AffiniPure Donkey Anti-Rabbit IgG (H+L)	Jackson ImmunoResearch	#711-625-152
Chemicals, Peptides and Recombinant Proteins		
Hoechst 33342	ThermoFisher Scientific	#62249
Triton X-100	Sigma-Aldrich	#T8787
Donkey serum	Millipore	#S30-100ML
Bovine serum albumin	Sigma	#A2153
KnockOut™ DMEM/F-12	Gibco	#12660012
Neurobasal medium	Gibco	#21103049
Penicillin-Streptomycin	Sigma	#P4333
Gibco GlutaMAX™ Supplement	ThermoFisher Scientific	#35050061
N-2 supplement	ThermoFisher Scientific	#17502048
B-27 supplement	ThermoFisher Scientific	#17504001
mTeSR-Plus Medium	StemCell Technologies	#100-0276
Accutase™ Cell Dissociation Reagent	Gibco	#11599686
ReLeSR™	StemCell Technologies	#100-0483
Matrigel®	Corning	#356230
Poly-l-ornithine	Sigma	#P4957

Purmorphamine	Tocris Bioscience	#4551
DMH-1	Tocris Bioscience	#4126
SB431542	Tocris Bioscience	#1614
CHIR99021	Tocris Bioscience	#4423
ROCK inhibitor (Y-27632 dihydrochloride)	Tocris Bioscience	#1254
Compound E	Tocris Bioscience	#6476
All-trans retinoic acid	Sigma	#R2625
Valproic acid	Sigma	#P4543
hBDNF	R&D systems	#248-BDB-010/CF
IGF-1	R&D systems	#291-G1
CNTF	R&D systems	#257-NT-010/CF
Dulbecco's Phosphate Buffered Saline	Sigma	#D8537-500ML
EDTA	Sigma	#E5134
HEPES	Sigma	#H3375
PMSF protease inhibitor	ThermoFisher Scientific	#36978
Protease inhibitor tablet	Roche	#1697498
TEMED	ThermoFisher Scientific	#17919
Ammonium Persulfate	ThermoFisher Scientific	#17874
30% Acrylamide/Bis-acrylamide solution	Sigma	#A3699-100ML
TE Buffer, RNAse-free pH 8	ThermoFisher Scientific	#AM9849
Ethidium bromide solution	Sigma	#E1510
VeriFi mix red	PCRBio	#PB10.42-01

Tri reagent	Sigma	#93289-100ML
M-MLV reverse transcriptase	ThermoFisher Scientific	#28025-013
5x First Strand buffer	ThermoFisher Scientific	#18057-018
0.1M Dithiothreitol	ThermoFisher Scientific	#707265ML
dNTP Mix	ThermoFisher Scientific	#10534823
Random hexamer primer	ThermoFisher Scientific	#SO142
SYBR Green Brilliant III master mix	Agilent	#600882
Critical Commercial Assays		
Protein Bradford Assay	Bio-Rad	#5000201
GenElute Mammalian Genomic DNA Miniprep Kit	Sigma	#G1N350
Direct-zol RNA Miniprep Kit	Zymo Research	#R2050
QIAquick PCR Purification kit	Qiagen	#28104
QIAquick Gel Extraction Kit	Qiagen	#28506
Experimental Models: Cell Lines		
GM23338 (iPSC line derived from healthy volunteer)	Coriell Institute	#CVCL_F182
KOLF2.1J (iPSC line derived from healthy volunteer)	The Jackson Laboratory	#HPSI0114i-kolf_2
C9-183 (iPSC line derived from a patient with C9orf72-ALS)	The University of Sheffield	#RRID:CVCL_UF85
C9-183_chr7:76,009,472:C>T (iPSC line derived from a patient with C9orf72-ALS with CRISPR-engineered enhancer edit [chr7:76,009,472:C>T])	The University of Sheffield	-
Software and Algorithms		

R v4.0.1	https://cran.r-project.org/mirrors.html	
PRISM 10	GraphPad	
ICE CRISPR analysis tool	https://ice.synthego.com/#/	
CFX Maestro	Bio-Rad	
Harmony Imaging Analysis Software	PerkinElmer (Revvity)	
FIJI (FIJI Is Just ImageJ)	NIH	
Incucyte® software	Sartorius	
Image Studio™ Software	LI-COR	
IGV v2.4.16	https://software.broadinstitute.org/software/igv/	
NeuroNet	https://github.com/szhang1112/neuronet	

RESOURCE AVAILABILITY

Lead contact

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Michael P. Snyder (mpsnyder@stanford.edu).

Material availability

All unique/stable reagents generated in this study are available from the Lead Contact without restriction.

Data availability

The epigenome and transcriptome profiling data of iPSC-derived motor neurons (iMN) used in the ABC model and NeuroNet are available at encodeproject.org with the following link: https://www.encodeproject.org/publications/de19555b-a49f-471c-bfbc-be3b628fe9bf/.
NeuroNet variant effect scores can be downloaded at https://doi.org/10.6084/m9.figshare.25444534. The Project MinE WGS data are accessible upon application approval (https://www.projectmine.com/research/data-sharing/). The

646 AnswerALS WGS and RNA-seq data are available upon request approval
647 (https://dataportal.answerals.org/home).

648 ***Code availability***

649 The NeuroNet source code and tutorial are available at
650 https://github.com/szhang1112/neuronet.

METHODS

Prediction of enhancer-promoter interactions using the ABC model

We implemented the ABC model following the guidelines provided at https://github.com/broadinstitute/ABC-Enhancer-Gene-Prediction. First, we called peaks for the iMN ATAC-seq profiling data[21] using MACS2, and then identified the candidate enhancer elements using "makeCandidateRegions.py" with peakExtendFromSummit = 250 and nStrongestPeaks = 150000. The black-listed regions generated by the ENCODE 4 (https://www.encodeproject.org/) were used for removing enhancers overlapping regions with anomalous sequencing reads. Second, we applied "run.neighborhoods.py" to quantify the enhancer activities by counting ATAC-seq and H3K27ac ChIP-seq reads in candidate enhancer regions. RNA-seq profiling of iMNs was also provided to inform expressed genes. Quantile normalization was applied using K562 epigenomic data as the reference. At last, using "predict.py" we computed the ABC scores by combining the enhancer activities (calculated by the second step) with the Hi-C profiling. Hi-C data were fit to the power-law model. The suggested threshold 0.02 was used to define valid E-P links.

NeuroNet model design and training

The architecture of NeuroNet follows the Beluga structure[12], a powerful convolutional neural network (CNN) designed to predict 2,002 epigenomic features from the DNA sequence, except the last layer of NeuroNet is tailored to predict four epigenomic features (chromatin accessibility, H3K27ac, H3K4me1, and H3K4me3) in iMNs.

The input of NeuroNet is the one-hot encoded 2,000-base-pair (bp) DNA sequence of which the centered 200 bp region overlaps peaks of at least one epigenomic feature – called valid sequence in this paper. The model outputs four probabilities indicating the peak status. Given the encoded input sequence X_i (i = 1, ..., N), the model f is trained to minimize the following binary cross-entropy loss:

$$L(\Omega) = \Sigma_{ij} (y_{ij} \cdot \log \sigma (f_j(X_i)) + (1 - y_{ij}) \cdot \log (1 - \sigma (f_j(X_i)))) / 4N,$$

Where j is the index of four epigenomic features, σ is the sigmoid function, y_{ij} is the binary label of the j-th feature of the i-th valid sequence, and Ω is the set of network parameters.

Genome-wide valid sequence samples were randomly split into 1270000, 4000, and 164080 training, validation, and testing samples, respectively. The dataset was further augmented by adding reverse complement sequences. Stochastic gradient descent (SGD) with learning rate = 0.1, momentum = 0.9, and weight decay = 1 x 10^{-6} was adopted as the

optimizer. Batch size was set to 256. We also applied early stopping to prevent overfitting, in

which the AUPRC was selected as the monitoring metric for an imbalanced dataset.

The network structure of NeuroNet follows the Beluga architecture which has been

widely used in biological sequence modeling. Following the best practice[11,12,50], we trained

NeuroNet based on 1,270,000 training examples and evaluated model prediction using

164,080 sequence-epigenome pairs held-out on chromosomes 8 and 9.

Variant effect prediction using NeuroNet

After the model was trained, we utilized NeuroNet to infer the functional effects of individual

variants on epigenomic features. Given a genetic variant, we construct a variant-centered DNA

sequence based on the reference genome, along with its reverse complement sequence. The

model predictions for both forward and reverse complement sequences are averaged to yield

the variant epigenomic scores $S_{alt,j}$. Similarly, the epigenomic scores $S_{ref,j}$ are also calculated.

We define the variant functional scores $S_{var,j}$ per epigenomic feature as the absolute difference

between reference and alternative epigenomic scores, i.e., $S_{var,j} = |S_{ref,j} - S_{alt,j}|$, where j indicates

different epigenomic features. The final NeuroNet score S_{NN} for each variant is defined as the

maximum of all functional scores, i.e., $S_{NN} = \max_j S_{var,j}$. As justified in the main text, we chose

0.06 as the threshold to define "functional noncoding variants" in MNs, that is, a noncoding

variant is kept for downstream analysis if and only if its NeuroNet score satisfies $S_{NN} > 0.06$.

Transcription factor binding motif analysis

The TF binding motif analysis was performed using GimmeMotifs[70]. The short-range and long-

range enhancers were defined as enhancers with the mean absolute E-P distance below 5%

and above 95% of the distribution, respectively. The differential motifs between short- and

long-range enhancers were identified using the "gimme maelstrom" command. This command

combined the results from different methods using the Stouffer's method, yielding an

integrated Z-score. A higher Z-score means the motif better matches the sequence of the peak

region in one condition than the other.

Network analysis

We downloaded the human PPIs from STRING version 12.0[71], including 19,622 proteins and

6,857,702 protein interactions. We extracted high-confidence (combined score >700) PPIs for

downstream analysis, including 16,185 proteins and 236,000 protein interactions. To eliminate

the bias caused by hub proteins[72], we ran the random walk with restart (RWR) algorithm over

the PPI network, wherein the restart probability was set to 0.5, resulting in a smoothed network

after preserving the top 5% predicted edges (N = 6,243,766). We then applied the Louvain

method[73], a classic community detection algorithm searching for densely connected modules,
to decompose the network into different modules. After the algorithm converged, we obtained
1,261 modules with an average size of 13 nodes.
The enrichment of genes of interest within each module was tested using the
hypergeometric test. Modules with false discovery rate (FDR) < 0.1 after the BH procedure
were reported.

Gene ontology analysis

724 The gene ontology (GO) analysis in this work was performed based on clusterProfiler[74] and
725 enrichR[75]. All enrichment analyses were focused on the biological process and molecular
726 function. The gene enrichment was evaluated based on a two-sided Fisher's exact test, and
727 only terms with adjusted P < 0.1 (after BH correction) were reported. To remove the GO term
728 redundancy in some cases, we applied the "simplify" function provided by clusterProfile.

Benchmarking of NeuroNet prediction against other variant scores

To benchmark NeuroNet against DeepSEA, the Pearson correlation between NeuroNet
prediction for four MN epigenomic features and DeepSEA prediction for matched epigenomic
features was calculated. For each MN epigenomic feature, all correlation coefficients were first
sorted and evenly divided into highly- and weakly-correlated sets, and then the rank of brain-
and neuron-related correlations was examined using a two-sided Fisher's exact test within
these two sets.
SNP2TFBS[24] was used to predict the variant effect on TF binding affinity. The binding
affinities for different TFs were averaged for each studied variant to estimate its overall effect.
Given a particular NeuroNet cutoff, the noncoding variants were split into two groups according
to their NeuroNet predictions. We compared the SNP2TFBS scores between these two groups
of variants and examined the difference using a two-sided t-test. The t-statistics were reported
to indicate the SNP2TFBS score difference between two groups. The final NeuroNet score
threshold was determined at the largest difference.
With the determined NeuroNet threshold, the correlation between NeuroNet prediction
and other scores was inspected by comparing scores between NeuroNet-positive and
NeuroNet-negative variants using a two-sided Fisher's exact test.

Whole-genome sequencing data in Project MinE

747 Project MinE WGS data (Data Freeze 2) consists of 6,715 ALS patients and 2,885 healthy
748 controls recruited at specialized neuromuscular centers in the UK, Belgium, Germany, Ireland,
749 Italy, Spain, Turkey, the United States and the Netherlands[76]. Patients were diagnosed with

possible, probable or definite ALS according to the 1994 El-Escorial criteria[77]. All controls were free of neuromuscular diseases and matched for age, sex and geographical location. Sample-level and variant-level quality controls (QCs) have been described previously[76]. Briefly, variants with missingness > 5% were removed, as were variants out of Hardy-Weinberg equilibrium (HWE) in controls ($P < 1 \times 10^{-6}$) and monomorphic variants. All samples had missingness <10% across all 22 chromosomes and samples with an inbreeding coefficient >3 standard deviations from the mean of the distribution were excluded, as were unexpected related samples. After QCs, 6,025 ALS genomes were retained for downstream analysis.

ALS survival and risk analysis based on NeuroNet-prioritized rare noncoding variants

After QCs, single nucleotide variants (SNVs) meeting all the following criteria were reserved for the survival analysis: (1) minor allele frequency (estimated based on non-Finnish European samples in the gnomAD whole-genome collection 2.1.1) < 0.5%; (2) minor allele count ≥ 3 within the QCed cohort; (3) residing within MN CREs (promoters and enhancers) defined by the ABC model; (4) NeuroNet score > 0.06. These criteria together defined the "functional rare noncoding variants" in our study. Next, screened variants were collapsed to their target genes based on the ABC E-P links and the number of total mapped variants for each gene was counted (i.e., gene burden). To associate the gene burden to survival, we applied the Cox proportional-hazards model implemented by the "coxph" function in the R "survival" package, with 26 covariates including age, sex, age^2, sex x age, sequencing platform, *C9orf72* status and the first 20 principal components. Because many genes shared the same group of regulatory variants resulting in duplicate tests, we collapsed those genes into unique sets and carried out the Bonferroni multiple testing correction. Tests with adjusted $P < 0.05$ were reported.

We also performed a case-control analysis by including the control samples in Project MinE. 2,264 controls were reserved for analysis after QCs. Functional rare noncoding variants were identified in the same way as that in the survival analysis, and then included in the case-control study. Gene burdens were calculated similarly. To associate gene burden to the disease status, we applied the SKAT-O method[30] implemented in the RVTESTS[30], with 25 covariates including age, sex, age^2, sex x age, sequencing platform, and the first 20 principal components.

Benchmarking of survival analysis

The benchmarking survival analysis was conducted the same as NeuroNet-powered survival analysis, except the NeuroNet score was not used for prioritizing noncoding variants.

Transcriptome analysis for the AnswerALS cohort

For AnswerALS dataset, RNA-seq data of iMNs and phenotype data were obtained for 245 ALS patients. Gene expression was normalized for gene length and then sequencing depth to produce transcripts per kilobase million (TPM) using Kallisto v0.46.0[78]. Read counts were trimmed Mean of M-values (TMM) normalized[79] to account for differences in library size. For each gene, based on the expression level in and outside the top 25%, patients were split into two groups – high-expression and low-expression groups. We used multivariable linear regression to determine the relationship between gene expression level and rate of change in the ALSFRS-R, and Cox proportional-hazards regression on two patient groups to determine the relationship between gene expression and survival time from symptom onset. In both cases, age of disease onset, sex, site of disease onset, and *C9orf72* status were included in the model as covariates. Significance testing was performed for all genes expressed in iMNs as determined by >0 read counts in more than half of samples, and mean read counts across all samples >25th percentile. The ALSFRS-R was scored from a maximum of 48 where a reduced score indicates increasing disability[69]. We calculated the rate of change in the ALSFRS-R (i.e., Δ(ALSFRS-R)) assuming a linear decline from a score of 48 at symptom onset.

CRISPR-editing of survival-associated genetic variant

The variant chr7:76,009,472:C>T (hg19 genome build, ENSEMBL) was introduced to *C9orf72*-ALS 183 iPSCs (passage 21) (RRID:CVCL_UF85) using CRISPR/Cas9-mediated homology directed repair (Synthego[80]). Donor sequence: GTGCCAGTCGCAGGCTCTCCAATCAGGAGGCTGCCGTGGGGCCAGGGGTGTGGCTCC GGTTCCCACGCGGGGCGAATTCCCTCTCCCGGTAGTCTCCCCAG. gRNA sequence: GGGAACCGGAGCCGCGCCCC. *C9orf72*-ALS 183 iPSCs were derived from a 51 year old Caucasian male with *C9orf72* G4C2 repeat expansion and a diagnosis of familial ALS at the time of sampling[81,82]. Editing efficiency was confirmed via Sanger sequencing using the following primers: fwd (5'-3'): CAGAAGCCCTGAGGAGTGC, rvs (5'-3'): GCCTCGGAGGTTTTTCTGGA. Sequencing traces were uploaded to the Synthego ICE Analysis tool (v3) (https://ice.synthego.com), and the indel efficiency within the mixed pool was calculated at 91%. Editing efficiency remained stable throughout motor neuron differentiation.

Sequence traces are available on request. CRISPR-edited cells were engineered by Synthego

(EditCo Bio).

Tissue culture of iPSCs and iMNs

iPSCs were cultured in mTesR Plus media (StemCell Technologies) in Matrigel-coated (8.7

ug/cm²) 6-well plates (Corning) and maintained at 37°C, 5% CO2. Cells were passaged when

~80% confluent using ReLeSR (StemCell Technologies), according to the manufacturer's

instructions. iPSCs were differentiated into neural progenitor cells (NPCs) using a modified

version of the dual SMAD inhibition protocol[21,83]. On the day after plating (day 1), after the

cells had reached ~100% confluence, the cells were washed once with PBS and the medium

was replaced with neural induction medium (50% of KnockOut DMEM/F-12, 50% of

Neurobasal), 0.5x N2 supplement (ThermoFisher), 1x Gibco GlutaMAX Supplement

(ThermoFisher), 0.5x B-27 supplement (ThermoFisher), 50 U ml−1 penicillin and 50 mg ml−1

streptomycin, supplemented with SMAD inhibitors (DMH-1 2 µm; SB431542 10 µm; and

CHIR99021 3 µm). This medium was changed every day for 6 days, and on day 7 the medium

was replaced with neuralization medium supplemented with DMH-1 2 µm, SB431542 10 µm

and CHIR 1 µm, All-Trans Retinoic Acid 0.1 µm (RA), and Purmorphamine 0.5 µm (PMN). The

cells were kept in this medium until day 12 when it was possible to observe a uniform

neuroepithelial sheet. At this point the cells were split 1:4 with Accutase (Gibco), onto matrigel

substrate in the presence of 10 µm ROCK inhibitor (Y-27632 dihydrochloride, Tocris), giving

rise to a sheet of neural progenitor cells (NPC). After 24 hours of incubation the medium was

changed to neural medium supplemented with RA 0.5 µm and PMN 0.1 µm, and the medium

was changed every day for 6 more days. On day 19 motor neuron progenitors were split with

accutase into plates pre-coated with poly-l-ornithine (10 µg/ml for 1hr at RT followed by 3x

washes in dH₂O) followed by matrigel (8.7 ug/cm² for 1hr at RT), and the medium was replaced

with motor neuron differentiation medium supplemented with RA 0.5 µm, PMN 0.1 µm,

compound E 0.1 µm (StemCell Technologies), BDNF 10 ng/mL, CNTF 10 ng/mL and IGF-1

10 ng/mL (Tocris) until day 28. On day 29, the media was replaced with neuronal maturation

media (neurobasal media supplemented with 1% of B27, BDNF 10 ng/mL, CNTF 10 ng/mL

and IGF-1 10 ng/mL). The cells were then fed every 72 hrs until day 40.

Treatment of cells with antisense oligonucleotides (ASOs)

843   iMN monocultures were treated with 5 µM of either a scrambled control
844   (GCGACTATACGCGCAATATG) or CCDC146-targeting (TGCTGACTAATTGTGGTTAC)
845   ASO (Integrated DNA Technologies) in neuronal maturation media for 72 hours prior to
846   downstream assessment of ciliary function by immunocytochemistry or immunoblotting.

Measurement of gene expression in iMNs

Gene expression was determined via quantitative real-time polymerase chain reaction (qRT-
PCR). Primer sequences were as follows: *FGL2: Fwd: TCAAAGTGTCCCAGCCAAGAA, Rvs:*
ACTCTGTAGGTCTCACTGCTTC. FAM185BP: Fwd: TCAGGGTCTGGCTGTGTAGA, Rvs:
TCCCAGACAGATCACTTTGCC. CCDC146: Fwd: ACTCCACAAAGCTCATCAGAAG, Rvs:
TCCTGAAGTTTTGATACAATTTTGC. RNA was extracted using a Direct-zol RNA Purification
Kits (Zymo) according to the manufacturer's instructions. 2µg of total RNA was converted to
cDNA in an initial reaction mixture containing 1µL 10mM dNTPs, 1µL 40µm random hexamer
primer (ThermoFisher Scientific), and DNAse/RNAse-free water to a total volume of 14µL.
This mixture was heated for 5 minutes at 70°C then incubated on ice for 5 minutes. 4µL of 5x
FS buffer, 2µL 0.1M DTT, and 1µL M-MLV reverse transcriptase (200U/µL) (ThermoFisher
Scientific) were then added, and cDNA conversion was performed in a PCR thermocycler
(37°C for 60 minutes, 85°C for 10 minutes). cDNA was amplified using RT-PCR with Brilliant
III SYBR Green (Agilent) as per the manufacturer's instructions. Ct analysis was performed
using CFX Maestro software (BioRad). β-actin was chosen as a reference gene because
expression is stable in iPSC-derived neurons[84]. qPCR products were sequenced to confirm
target specificity and sequence traces are available on request. Statistical analysis was
performed using GraphPad Prism version 10.0.0.

Longitudinal survival tracking of iMNs

866   Survival of iMN was assessed from day 28-40 using an Incucyte® Live Cell Analysis System
867   (Sartorius) at 20x magnification across 3 biological repeats. Neurite length (mm/mm^2) was
868   used as a readout for cell survival. For each biological repeat, 10 wells were imaged per group
869   with 9 fields of view per well. The neurotrack module (Sartorius) was used to determine neurite
870   metrics from brightfield images. In each case statistical significance was calculated by

applying a paired *t*-test at each timepoint. Statistical analysis was performed using GraphPad Prism version 10.0.0.

Immunocytochemistry

For immunostaining, neural progenitor cells (NPC) and motor neurons (MN) were washed with phosphate-buffered saline (PBS) and fixed with 4% paraformaldehyde for 10 min at room temperature. After fixation samples were washed three times with PBS and permeabilized with 0.3% Triton X-100 diluted in PBS for 5 min. The cells were subsequently blocked in 5% Donkey serum (Millipore) for 1h at room temperature (RT). After blocking, cells were incubated with the appropriate primary antibodies: mouse anti-nestin 1:200 [Abcam #ab22035]; rabbit anti-Pax6 1:50 [Abcam #ab5790]; guinea pig anti-MAP2 1:1000 [Synaptic Systems #188004]; chicken anti-TUJ1 1:1000 [Merck Millipore #AB9354]; mouse anti-SMI32 1:1000 [Biolegend #801701]; rabbit anti-HB9 1:250 [Abcam #ab221884]; goat anti-ChAT 1:50 [Merck #AB144P]; rabbit anti-CCDC146 [Atlas Antibodies #HPA020082] diluted in PBS containing 5% of DS overnight. Cells were then washed with PBS three times. Fluorescent secondary antibodies (Alexa Fluor 488, 561, or 647, diluted 1:1000 with 5% DS) (ThermoFisher Scientific #A-21202, #A-21432, A-21450, #A-32744, #A-21206) were subsequently added to the cells and incubated for 1h at RT. The samples were washed with PBS three more times and incubated with Hoechst 33342 (Invitrogen) for nuclear staining for 5 minutes. For primary cilium staining, a CoraLite® Plus 488-conjugated ARL13B polyclonal antibody (Proteintech #CL488-17711) was applied for 1hr after all washes to limit cross-reactivity with other primary antibodies of the same species. All experiments included cultures where the primary antibodies were not added; non-specific staining was not observed in these negative controls. Images were obtained using an Opera Phenix™ High Content Screening System (Revvity) at 40x magnification to generate a high-resolution z-stack at 0.5 µm intervals throughout the entire nuclear volume of the cell. Images were analyzed using the Harmony™ Image analysis system. 488, 561, and 647 nm lasers along with the appropriate excitation and emission filters were used. These settings were kept consistent while taking images from all separate differentiations.

Measurement of cilia length

CIlia length was the longest dimension of cilia immunostaining measured in maximum projection through visualised cilia. Each motor neuron has only one cilium. A technical replicate was taken to be the mean cilium length in a single field of view from at lest three separate motor neuron differentiations per condition. A paired t-test was used to determine statistical significance and account for variability between motor neuron differentiations.

Measurement of microtubule dynamics

iPS-MN were transfected with 1 µg EB3_mScarlet (Addgene #98826, kindly gifted from the Dorus Gadella lab) at day 39 using Lipofectamine™ 3000 (ThermoFisher Scientific), according to the manufacturer's guidelines. For live imaging by TIRF microscopy 24 hours post transfection, cells were cultured in phenol red-free neurobasal media supplemented with 10mM Hepes, 1% B-27 supplement, and imaged using a custom-built Nikon microscope with an iLas2 multi-application unit (Gataca Systems). Time-lapse imaging of EB3 comets within axons was performed at 200 ms intervals for 2 minutes using a 568 nm laser. Axons were straightened with the segmented line tool in FIJI, resliced, and then converted into kymographs using a maximum intensity z-projection. The velocity of EB3 comets was analysed using the FIJI plugin, TrackMate[85].

Western blotting

iMN were lysed on ice in IP-lysis buffer (50 mM Hepes pH7.5, 150 mM NaCl, 10% glycerol, 0.5% Triton X-100, 1 mM EDTA, 1 mM DTT, protease inhibitor cocktail (Sigma)), passed 10x through 25-guage needles and incubated on ice for 10 minutes. Samples were centrifuged at 17,000 xg for 5 minutes at 4°C. Protein extracts were quantified using Bradford Reagent (BioRAD), resolved by SDS–PAGE (15% resolving gel; 5% stacking gel), and electroblotted onto nitrocellulose membranes. Membranes were blocked in 5% BSA + TBST (20 mM Tris, 137 mM NaCl, 0.2% (v/v) Tween® 20, pH 7.6) for 1 hour at room temperature (RT). Membranes were probed using the relevant primary antibody [anti-CRABP1 (1:1000 dilution), Proteintech #12588-1-AP; anti-TUJ1 (1:1000 dilution), Abcam #ab18207] diluted in 5% BSA + TBST overnight at 4°C. Membranes were washed 3x in TBST, incubated with an Alexa Fluor 680-AffiniPure Donkey Anti-Rabbit IgG (H+L) secondary antibody (Jackson #711-625-152) diluted in TBST for 1 hour at RT, and washed 3x in TBST. Fluorescence signal intensity was analysed using the Odyssey® Fc Imaging System (LI-COR Biosciences).

Generation of iPSC-derived 3D-induced neurons

To generate iPSC-derived 3D-induced neurons (3D-iNs), iPSCs were first co-transfected (Lipofectamine Stem, Thermofisher) with a piggybac expression cassette containing a dox-inducible h*NGN2* transgene and mApple fluorescent reporter (addgene 182308) and the Super piggyBac Transposase expression vector (SBI). After a brief (24h) recovery, transfected iPSCs were replated using accutase+10µm ROCK-inhibitor (Ri, Selleckchem) at sparse densities where an initial selection with 20µm blasticidin (Cayman, BSD) was performed. BSD concentrations were increased until a highly pure population of mApple fluorescent cells were observed and subsequently used for downstream studies. To generate the 3D-iN cultures,

iPSCs expressing the h*NGN2* piggybac construct were dissociated with accutase and 10μm
ROCK-inhibitor (Selleck) and seeded into Matrigel coated 6-well plates at ~200,000 cells per
well in induction medium containing DMEM+Glutamax (Thermofisher), NEAA (Gibco), 1%
penicillin/streptomycin, N2 supplement (Gibco) , and 10ng/ml each of BDNF (R&D) and NT-3
(Peprotech) plus doxycycline (2μg/mL) to drive the expression of the h*NGN2* cassette. 48
hours after induction, induction medium was replenished and BSD (20-40μg/mL) was added
if non-converting, non-transgenic cells were observed. 72 (Day 3) hours after induction, BrdU
(Millipore Sigma) at 40μm was added to eliminate dividing cells. By Day 5 of induction, the
pure population of converting iNs were replated using accutase and Ri (20μM) to ultra-low
attachment 96-well U-bottom plates (Corning) containing neuronal maintenance medium
(MM): neurobasal (Thermofisher), N2 and B27 supplements (Gibco),
1%penicillin/streptomycin, glutamax (Thermofisher, 100x), and NEAA (Thermofisher, 100x)
plus BDNF and NT-3 (10ng/mL each) at densities of ~50,000-80,000 neurons per well, where
the cells would coalesce into 3D-iN cultures. 3D-iNs were maintained in this format until Day
40 for survival tracking with medium changes (MM plus BDNF and NT3) every 3 days.

3D-iN longitudinal survival tracking

3D-iNs were allowed to mature until Day 30 after dox and were then transduced with a
SYN1::GFP lentivirus to enable labeling of individual neurons as previously described[45,48]. 72-
hours prior to the start of the survival assay (Day 37 after Dox), 3D-iNs were treated with ASO
gapmers designed using an in-house strategy; 10μm of either a scrambled or *CCDC146* ASO
were administered via gymnotic uptake. On Day 39 (24 hours prior to start of tracking), 3D-
iNs were embedded in 100% Matrigel (Corning) for 30 minutes to allow gelling. MM was
replenished after the 3D-iNs were fixed. Following a baseline image at Day 0 of the tracking
(Day 40 of differentiation), glutamate (L-Glutamic acid monosodium salt hydrate; 5mM
Milipore) was added to the medium and replenished every other day thereafter. Continuous z-
stacks starting from the 3D-iN surface were captured every other day (from Day 0) using a
Zeiss AxioZoom.v16 wide-field upright fluorescence microscope. Image processing and
analysis were performed using ImageJ software (NIH). To quantify neuronal death ~100
neurons were tracked across 4 replicates per line per condition. Hazard ratios (HR) were
calculated using the log-rank method; for each replicate across each condition, the HR was
calculated as a comparison to the aggregate survival of the scrambled ASO control spheroids.

hTDP43 mouse studies

Mouse strains C57BL/6J and B6;SJL-Tg(Thy1-TARDBP)4Singh/J (stock number: 012836)
were purchased from the Jackson Laboratory. The murine Thy1 promoter drives expression

of human TDP-43 in neurons and other CNS/PNS cells. Animals were housed in a temperature and humidity-controlled environment under standard conditions with access to food and water ad libitum. Animals were subjected to 12-hour light/dark cycles. All animal care and experimental procedures were performed in accordance with local institution guidelines of the University of Southern California and approved by the Institutional Animal Care and use Committee of the University of Southern California (protocol number: 11938).

hTDP43 transgenic mice were purchased from the Jackson Laboratory (stock number: 012836). hTDP43$^{Tg/Tg}$ homozygous mutant mice were generated by crossing hTDP43$^{Tg/+}$ heterozygous mice with hTDP43$^{Tg/+}$ heterozygous mice. Genotyping primers are as follows: Common primer: (5'- TGAAATCCGGGTGGTATTGG-3'); WT primer: (5'-GGTGAGTTTAACCTTCAAGGGCT-3'); Transgene primer: (5'-AGCTTGCTAGCGGATCCAGAC-3'). Homozygous transgenic mice were identified by a single, 500 bp band, heterozygotes with a 303 bp and 500 bp bands, and wild-type (WT) mice with a single 303 bp band. Homozygous transgenic animals and their WT littermate controls were used for the subsequent ASO studies.

ASO mouse treatments

25µg of a negative control or Ccdc146 ASO were administered by intracerebroventricular (ICV) injection at post-natal day 1 (P1). ASOs were ordered from Integrated DNA Technologies and were designed with chemical modifications to improve their potency and efficiency for gene knockdown. Phosphorothioate linkages were used within the sequence to provide resistance to nucleases, the 2'-O-methoxy-ehtyl (MOE) modification was added to enhance nuclease stability and binding affinity for the target RNA. ASOs were ordered with additional HPLC and sodium/salt exchange purification steps to remove potentially toxic byproducts during synthesis. Purity of the ASOs was confirmed by IDT via mass spectrometry. ASO sequences used in these studies are as follows (m=2'-O-Methyl, *-phosphorothioate linkage, MOE = 2'-Methoxyethyl): msNC ASO: /52MOErC/*/i2MOErC/ /i2MOErT/ /i2MOErA/ /i2MOErT/ A*G*G*A*C*T*A*T*C*C*/i2MOErA/ /i2MOErG/ /i2MOErG/* /i2MOErA/*/32MOErA/; msCcdc146 ASO: /52MOErC/*/i2MOErA/ /i2MOErA/ /i2MOErT/ /i2MOErC/ T*G*C*T*G*C*T*C*C*A*/i2 MOErC//i2MOErT/ /i2MOErA/* /i2MOErA/*/32MOErC/

ICV injection procedure

D1 neonatal mice were anesthetized by placing them on a paper towel lined bucket of ice to induce hypothermia. The injection site targeting the lateral ventricles was defined as 2/5 the distance from the anatomical landmark, lambda to the eye. To perform the ICV injection, a 900 series Hamilton syringe (10µL) adapted with the bottom portion of Neuros model 1701

RN syringe. A 33-gauge needle was inserted 2mM deep, perpendicular to the skull surface
into the lateral ventricle (left). Mice received 3µL of the respective NC ASO or Ccdc146 ASO
in PBS (25µg). Following the injection, mice were placed under a heat lamp in a new cage
containing soiled bedding from the parental cage and were monitored until they had fully
recovered. Motor phenotyping (gait, kyphosis, and tremor) was examined starting at P14 and
recorded every other day until D22. Phenotype score was determined according to a rubric
previously reported (PMID: 28405022). A higher score denotes a more severe phenotype
(0=no phenotype, 4=most severe/end stage). The humane euthanasia endpoint was
established to be when the mouse was no longer able to right itself. Hydrogel, powdered
pellets, and high caloric diet gel were placed on the bottom of each cage containing the mutant
mice.

Mouse tissue collection

WT or hTDP43$^{Tg/Tg}$ were treated with a NC ASO or Ccdc146 ASO at postnatal day 1 via ICV
injection. For tissue collection for, D22 mice were anesthetized and intracardiac perfusion was
performed first with PBS and then with 4% PFA in PBS, the tissue was then fixed in 4% PFA
for another 4 hours. Tissue was then incubated in 15% sucrose in PBS+.01% sodium azide
for 24 hours and then 30% sucrose in PBS +.01% sodium azide for another 48 hours prior to
embedding and immunofluorescence analysis. For RNA isolation, mice were euthanized and
isolated brains were separated into two hemispheres, one hemisphere and spinal cords were
lysed for RNA analysis and the other was frozen at -80°C.

Mouse histology

Cryoprotected tissues were embedded in O.C.T (Fisher, cat: 23730571) and cryosectioned
into 16µM slices using a Leica CM3050S cryostat onto Superfrost Plus Microscope slides
(Fisher) and stored at -80°C until use. For spinal cord neuron counts, lumbar spinal cord
sections were rehydrated in 10x PBS for >40 minutes and washed in PBS+.1% Triton X-100
for 10 minutes. Slides were then washed in PBS for 2, 5-minute washes. The slides were then
incubated with NeuroTrace (Fluorescent Nissl Stain, Thermo N2148) diluted 1:50 in PBS for
20 minutes in the dark. After removing the stain, slides were washed for another 10 minuites
in PBS+.1% Triton-X-100 for 10 minutes, 2x5 minute washes in PBS and 2 hours at room
temperature/overnight at 4°C in PBS prior to mounting. To quantify the neurons in the ventral
horn region of the spinal cord, 3 sections per animal were stained with NeuroTrace and image
using a Zeiss LSM 800 microscope. The lateral motor column was used for analysis. The
counts were quantified based on the average total neuron counts in the lumbar hemicords
across all 3 sections per animal, per treatment condition. To quantify the cellular localization

of TDP43/tdp43, the nuclear and cytoplasmic fluorescence intensity was measured using an
antibody with reactivity for both murine and human protein (10782-2-AP, Proteintech, 1:400).
The fluorescence intensity of the TDP43 staining in the cell nucleus and cytoplasm were
measured using Image J and recorded as the nuclear to cytoplasmic ratio. TUJ1+ motor
neurons in the ventral spinal cord were imaged using Zeiss LSM 800 with oil immersion at
63x. 15–25 neurons were quantified per animal.

Small-molecule drug search

We searched chemical activity databases ChEMBL[86] and PubChem[87] for CCDC146 and its
similar proteins, but did not obtain any active compounds for these proteins. Here, similar
proteins were defined as those with at least 50% sequence identities to the canonical
sequence of human CCDC146 protein, provided by the UniProt database[88]. We also searched
patent databases including WIPO (https://patentscope.wipo.int/), EPO
(https://www.epo.org/en/searching-for-patents) and USPTO
(https://www.uspto.gov/patents/search), using search terms "CCDC146" and "coiled-coil
domain-containing protein 146", to confirm that there is currently no available drugs for this
target.

Protein structure and binding site prediction

The predicted protein structure of CCDC146 protein was obtained from the AlphaFold Protein
Structure Database[89] (https://alphafold.ebi.ac.uk/). To evaluate the druggability of CCDC146,
we predicted potential ligand binding sites on its surface and obtained negative prediction
results using P2Rank[67], which is an accurate ligand binding site prediction tool.

Supplementary Figures

Supplementary Fig. 1. Enhancer-promoter (E-P) interactions in human motor neurons.
(**A**) Graphical illustration of the ABC model. TSS, transcription start site; E, enhancer; G, gene.
(**B**) Distribution of distance from enhancer to TSS. (**C**) Statistics of E-P links, including number
of enhancers per gene, number of genes per enhancer, and number of genes skipped by
enhancer. enh, enhancer. (**D**) Overlap between E-P links in MNs and those in neuronal cells
(NeuN+). (**E**) Distribution comparison of E-P links between MNs and neuronal cells. Density
curves were added. Dashed vertical lines represent distribution medians. *P*-value by two-side
t-test. (**F**) Differential motif enrichment between long-range and short-range E-P links. LR,
long-range; SR, short-range. (**G**) Network module enriched with genes targeted by short-range
E-P links. *P*-value by hypergeometric test. (**H**) Gene ontology (GO) enrichment for M56 genes.

Redundant GO terms were removed using the "simplify" function provided by "clusterProfiler".

GO terms with adjusted $P < 0.1$ were visualized. P-value by two-sided Fisher's exact test.

Supplementary Fig. 2. Additional results for E-P links and NeuroNet prediction. (**A**) Gene
ontology (GO) enrichment for genes with short-range enhancers in iPSNs. GO terms with
adjusted $P < 0.1$ (BH correction) were shown. P-value by two-sided Fisher's exact test. (**B-D**)
Pearson correlations between NeuroNet and DeepSEA predictions for H3K4me3 (**B**),
H3K27ac (**C**), and ATAC (**D**). P-value by two-sided Fisher's exact test. Neuron- and brain-
related tissues and cell types were highlighted. PCC, Pearson correlation coefficient.

Supplementary Fig. 3. Additional results for rare variant burden analyses. (**A**) Regulatory
relationships between chr2:51,259,489:G>C and target genes. Peak signals from MNs derived
from CS14-iPSCs were visualized. Significant genes in NeuroNet-informed survival analysis
were highlighted in red. CRE, cis-regulatory element. (**B**) Quantile-quantile (QQ) plot of a
standard rare variant burden-based survival analysis without NeuroNet-based variant filtering.
Genes sharing the same set of variants were collapsed into groups. (**C**) Overlap of genes
between survival and risk analysis with different P-value cutoffs. Overlap was examined by
two-sided Fisher's exact test. The dot and error bar indicate the odds ratio and 95% CI,
respectively. The dashed gray line represents odds ratio = 1. CI, confidence interval.

Supplementary Fig. 4. Additional results for CRISPR/Cas9-mediated modeling of
chr7:76,009,472:C>T in iPSC-derived *C9orf72*-ALS MNs. (**A**) Representative images of
iPSC-derived MNs (iMN). Top panels: isogenic control; bottom panels: edited. iMNs were
studied at day 40 post-iPSC-stage when they expressed a battery of neuronal markers,
including SMI-32, MAP2, and TUJ1. Scale bar: 50μm. (**B**) Quantification of the number of
neurite branch-points in an age- and sex-matched normal control, an isogenic control carrying
a G4C2-repeat expansion of *C9orf72*, and chr7:76,009,472:C>T-edited iMNs across 12 days
of tracking using an Incucyte live-cell analysis system (Sartorius). The dot and error bar
represent the mean and standard error, respectively. (**C**) Representative images from day 1
and day 11 for isogenic control neurons carrying a G4C2-repeat expansion of *C9orf72* (top
panels) and chr7:76,009,472:C>T-edited neurons (bottom panels). Cell soma are coloured
yellow and neurites are coloured purple. Scale bar 1.6mm. (**D**) Immunocytochemistry for
CCDC146 and primary cilia stained with Arl13b in iMNs derived from a neurologically healthy
control. Scale bar: 50μm.

Supplementary Fig. 5. Additional results for ASO suppression of *CCDC146* in ALS
patient-derived neurons. (**A**) Kaplan-Meier (KM) estimator plots of 3D-iN survival starting
(day 0) from day 40 after initiation of iPSC differentiation. The shaded area represents 95%

confidence interval (CI). *P*-value by log-rank test. C9, *C9orf72*; sALS, sporadic ALS; ctrl, control. (**B**) Representative images of control iNs treated with the scrambled ASO (top panels) or the *CCDC146* ASO (bottom panels). Images were taken from approximately the same location on the plat at Day 0 (left panels) and Day 8 (right panels) showing no obvious toxicity. Scale bar: 200μm. Ctrl, control. (**C**) Quantification of *CCDC146* mRNA expression via q-RT-PCR in *n* = 1 control line and *n* = 8 ALS patient-derived iN lines. *n* = 3 technical replicates per cell line. The central bar and error bar represent the mean and standard error, respectively. The red dashed line indicates control expression level. *P*-value by the Dunnett's test. **, adjusted *P* < 0.01; ****, adjusted *P* < 0.0001; ns, not significant; #, patient cell lines used in ASO experiments. (**D**) Immunocytochemistry for primary cilia stained with Arl13b across different treatments. Scale bar: 50μm.

Supplementary Fig. 6. The AlphaFold-predicted three-dimensional structure of CCDC146 protein. (**A**) The carton illustration of the predicted protein structure of CCDC146, obtained from https://alphafold.ebi.ac.uk/entry/Q8IYE0. pLDDT, predicted local distance difference test. (**B**) Protein surface of the predicted structure, illustrated using PyMol (https://pymol.org/).

Supplementary Fig. 7. Relationship between *ZNF839* expression and clinical markers of disease progression. (**A**) Correlation between the expression of *ZNF839* and rate of disease progression as measured by clinical symptoms. The ALSFRS-R is scored from a maximum of 48 with a reduction in the score signifying increased disability. The red line indicates the regression line; the gray area represents the standard error. *P*-value by multivariable linear regression with sex, age of onset, site of onset, and *C9orf72* status as covariates. (**B**) Kaplan-Meier (KM) estimator plots of patients with high and low *ZNF839* expression. Gene expression level in the top 25% was defined as "high expression" (*n* = 59), otherwise as "low expression" (*n* = 176). The difference in mean survival between two groups was 0.75 years. *P*-value by Cox proportional-hazards (PH) regression.

Supplementary Tables

Supplementary Table 1. Enhancer-promoter links in iPSC-derived motor neurons

Supplementary Table 2. Summary statistics of SKAT-O test for ALS risk

Supplementary Table 3. Summary statistics of NeuroNet-powered rare variant burden test for ALS survival

Supplementary Table 4. Summary statistics of rare variant burden test for ALS survival without variant filtering

1140 **Supplementary Table 5.** Clinical phenotypes of sequenced ALS patients carrying survival-

1141 associated rare noncoding variants

1142 **Supplementary Table 6.** Clinical phenotypes of patient iPSC lines

1143

1144

References

1. Feldman, E.L., Goutman, S.A., Petri, S., Mazzini, L., Savelieff, M.G., Shaw, P.J., and
Sobue, G. (2022). Amyotrophic lateral sclerosis. Lancet *400*, 1363–1380.
2. Chiò, A., Logroscino, G., Hardiman, O., Swingler, R., Mitchell, D., Beghi, E., Traynor,
B.G., and Eurals Consortium (2009). Prognostic factors in ALS: A critical review.
Amyotroph. Lateral Scler. *10*, 310–323.
3. Cooper-Knock, J., Hewitt, C., Highley, J.R., Brockington, A., Milano, A., Man, S.,
Martindale, J., Hartley, J., Walsh, T., Gelsthorpe, C., et al. (2012). Clinico-pathological
features in amyotrophic lateral sclerosis with expansions in C9ORF72. Brain *135*, 751–
764.
4. Al-Chalabi, A., van den Berg, L.H., and Veldink, J. (2017). Gene discovery in
amyotrophic lateral sclerosis: implications for clinical management. Nat. Rev. Neurol.
13, 96–104.
5. Cooper-Knock, J., Harvey, C., Zhang, S., Moll, T., Timpanaro, I.S., Kenna, K.P.,
Iacoangeli, A., and Veldink, J.H. (2021). Advances in the genetic classification of
amyotrophic lateral sclerosis. Curr. Opin. Neurol. *34*, 756–764.
6. Li, X., Li, Z., Zhou, H., Gaynor, S.M., Liu, Y., Chen, H., Sun, R., Dey, R., Arnett, D.K.,
Aslibekyan, S., et al. (2020). Dynamic incorporation of multiple in silico functional
annotations empowers rare variant association analysis of large whole-genome
sequencing studies at scale. Nat. Genet. *52*, 969–983.
7. Zhang, F., and Lupski, J.R. (2015). Non-coding genetic variants in human disease.
Hum. Mol. Genet. *24*, R102–R110.
8. Almeida, N., Chung, M.W.H., Drudi, E.M., Engquist, E.N., Hamrud, E., Isaacson, A.,
Tsang, V.S.K., Watt, F.M., and Spagnoli, F.M. (2021). Employing core regulatory circuits
to define cell identity. EMBO J. *40*, e106785.
9. GTEx Consortium, Laboratory, Data Analysis &Coordinating Center (LDACC)—Analysis
Working Group, Statistical Methods groups—Analysis Working Group, Enhancing GTEx
(eGTEx) groups, NIH Common Fund, NIH/NCI, NIH/NHGRI, NIH/NIMH, NIH/NIDA,
Biospecimen Collection Source Site—NDRI, et al. (2017). Genetic effects on gene
expression across human tissues. Nature *550*, 204–213.
10. Li, X., Kim, Y., Tsang, E.K., Davis, J.R., Damani, F.N., Chiang, C., Hess, G.T., Zappala,
Z., Strober, B.J., Scott, A.J., et al. (2017). The impact of rare variation on gene
expression across tissues. Nature *550*, 239–243.
11. Zhou, J., and Troyanskaya, O.G. (2015). Predicting effects of noncoding variants with
deep learning–based sequence model. Nat. Methods *12*, 931–934.
12. Zhou, J., Theesfeld, C.L., Yao, K., Chen, K.M., Wong, A.K., and Troyanskaya, O.G.

(2018). Deep learning sequence-based ab initio prediction of variant effects on
expression and disease risk. Nat. Genet. *50*, 1171–1179.

13. Kelley, D.R., Reshef, Y.A., Bileschi, M., Belanger, D., McLean, C.Y., and Snoek, J.
(2018). Sequential regulatory activity prediction across chromosomes with convolutional
neural networks. Genome Res. *28*, 739–750.

14. Avsec, Ž., Agarwal, V., Visentin, D., Ledsam, J.R., Grabska-Barwinska, A., Taylor, K.R.,
Assael, Y., Jumper, J., Kohli, P., and Kelley, D.R. (2021). Effective gene expression
prediction from sequence by integrating long-range interactions. Nat. Methods *18*,
1196–1203.

15. Yuan, H., and Kelley, D.R. (2022). scBasset: sequence-based modeling of single-cell
ATAC-seq using convolutional neural networks. Nat. Methods *19*, 1088–1096.

16. Agarwal, V., and Shendure, J. (2020). Predicting mRNA Abundance Directly from
Genomic Sequence Using Deep Convolutional Neural Networks. Cell Rep. *31*, 107663.

17. Wils, H., Kleinberger, G., Janssens, J., Pereson, S., Joris, G., Cuijt, I., Smits, V.,
Ceuterick-de Groote, C., Van Broeckhoven, C., and Kumar-Singh, S. (2010). TDP-43
transgenic mice develop spastic paralysis and neuronal inclusions characteristic of ALS
and frontotemporal lobar degeneration. Proc. Natl. Acad. Sci. U. S. A. *107*, 3858–3863.

18. Muroňová, J., Kherraf, Z.-E., Giordani, E., Eckert, S., Cazin, C., Amiri-Yekta, A.,
Lambert, E., Chevalier, G., Martinez, G., Neirijnck, Y., et al. (2023). Lack of CCDC146,
a ubiquitous centriole and microtubule-associated protein, leads to non-syndromic male
infertility in human and mouse. bioRxiv, 2023.02.27.530236.
https://doi.org/10.1101/2023.02.27.530236.

19. De Decker, M., Zelina, P., Moens, T.G., Beckers, J., Contardo, M., Dittlau, K.S., Van
Schoor, E., Ronisz, A., Eggermont, K., Moisse, M., et al. (2024). *C21ORF2* mutations
point towards primary cilia dysfunction in amyotrophic lateral sclerosis. Brain.
https://doi.org/10.1093/brain/awae331.

20. Fulco, C.P., Nasser, J., Jones, T.R., Munson, G., Bergman, D.T., Subramanian, V.,
Grossman, S.R., Anyoha, R., Doughty, B.R., Patwardhan, T.A., et al. (2019). Activity-by-
contact model of enhancer-promoter regulation from thousands of CRISPR
perturbations. Nat. Genet. *51*, 1664–1669.

21. Zhang, S., Cooper-Knock, J., Weimer, A.K., Shi, M., Moll, T., Marshall, J.N.G., Harvey,
C., Nezhad, H.G., Franklin, J., Souza, C.D.S., et al. (2022). Genome-wide identification
of the genetic basis of amyotrophic lateral sclerosis. Neuron *110*, 992–1008.e11.

22. Richter, F., Morton, S.U., Kim, S.W., Kitaygorodsky, A., Wasson, L.K., Chen, K.M.,
Zhou, J., Qi, H., Patel, N., DePalma, S.R., et al. (2020). Genomic analyses implicate
noncoding de novo variants in congenital heart disease. Nat. Genet. *52*, 769–777.

23. GTEx Consortium (2020). The GTEx Consortium atlas of genetic regulatory effects

across human tissues. Science *369*, 1318–1330.

24. Kumar, S., Ambrosini, G., and Bucher, P. (2017). SNP2TFBS - a database of regulatory
SNPs affecting predicted transcription factor binding site affinity. Nucleic Acids Res. *45*,
D139–D144.

25. Davydov, E.V., Goode, D.L., Sirota, M., Cooper, G.M., Sidow, A., and Batzoglou, S.
(2010). Identifying a High Fraction of the Human Genome to be under Selective
Constraint Using GERP++. PLoS Comput. Biol. *6*, e1001025.

26. Ritchie, G.R.S., Dunham, I., Zeggini, E., and Flicek, P. (2014). Functional annotation of
noncoding sequence variants. Nat. Methods *11*, 294–296.

27. Kircher, M., Witten, D.M., Jain, P., O'Roak, B.J., Cooper, G.M., and Shendure, J.
(2014). A general framework for estimating the relative pathogenicity of human genetic
variants. Nat. Genet. *46*, 310–315.

28. Huang, Y.-F., Gulko, B., and Siepel, A. (2017). Fast, scalable prediction of deleterious
noncoding variants from functional and population genomic data. Nat. Genet. *49*, 618–
624.

29. Project MinE: study design and pilot analyses of a large-scale whole-genome
sequencing study in amyotrophic lateral sclerosis (2018). Eur. J. Hum. Genet. *26*, 1537–
1546.

30. Lee, S., Emond, M.J., Bamshad, M.J., Barnes, K.C., Rieder, M.J., Nickerson, D.A.,
NHLBI GO Exome Sequencing Project—ESP Lung Project Team, Christiani, D.C.,
Wurfel, M.M., and Lin, X. (2012). Optimal unified approach for rare-variant association
testing with application to small-sample case-control whole-exome sequencing studies.
Am. J. Hum. Genet. *91*, 224–237.

31. Zhan, X., Hu, Y., Li, B., Abecasis, G.R., and Liu, D.J. (2016). RVTESTS: an efficient and
comprehensive tool for rare variant association analysis using sequence data.
Bioinformatics *32*, 1423–1426.

32. Nicolas, A., Kenna, K.P., Renton, A.E., Ticozzi, N., Faghri, F., Chia, R., Dominov, J.A.,
Kenna, B.J., Nalls, M.A., Keagle, P., et al. (2018). Genome-wide Analyses Identify
KIF5A as a Novel ALS Gene. Neuron *97*, 1268–1283.e6.

33. Baron, D.M., Fenton, A.R., Saez-Atienzar, S., Giampetruzzi, A., Sreeram, A.,
Shankaracharya, Keagle, P.J., Doocy, V.R., Smith, N.J., Danielson, E.W., et al. (2022).
ALS-associated KIF5A mutations abolish autoinhibition resulting in a toxic gain of
function. Cell Rep. *39*, 110598.

34. Li, C., Wei, Q., Hou, Y., Lin, J., Ou, R., Zhang, L., Jiang, Q., Xiao, Y., Liu, K., Chen, X.,
et al. (2023). Genome-wide analyses identify NEAT1 as genetic modifier of age at onset
of amyotrophic lateral sclerosis. Mol. Neurodegener. *18*, 77.

35. Kuriyama, S., Tamiya, Y., and Tanaka, M. (2017). Spatiotemporal expression of UPK3B

and its promoter activity during embryogenesis and spermatogenesis. Histochem. Cell

Biol. *147*, 17–26.

36. Shi, Y., Lin, S., Staats, K.A., Li, Y., Chang, W.-H., Hung, S.-T., Hendricks, E., Linares,

G.R., Wang, Y., Son, E.Y., et al. (2018). Haploinsufficiency leads to neurodegeneration

in C9ORF72 ALS/FTD human induced motor neurons. Nat. Med. *24*, 313–325.

37. Fiesel, F.C., Schurr, C., Weber, S.S., and Kahle, P.J. (2011). TDP-43 knockdown

impairs neurite outgrowth dependent on its target histone deacetylase 6. Mol.

Neurodegener. *6*, 64.

38. Klim, J.R., Williams, L.A., Limone, F., Juan, I.G.S., Davis-Dusenbery, B.N., Mordes,

D.A., Burberry, A., Steinbaugh, M.J., Gamage, K.K., Kirchner, R., et al. (2019). ALS-

implicated protein TDP-43 sustains levels of STMN2, a mediator of motor neuron growth

and repair. Preprint, https://doi.org/10.1038/s41593-018-0300-4

https://doi.org/10.1038/s41593-018-0300-4.

39. Neumann, M., Sampathu, D.M., Kwong, L.K., Truax, A.C., Micsenyi, M.C., Chou, T.T.,

Bruce, J., Schuck, T., Grossman, M., Clark, C.M., et al. (2006). Ubiquitinated TDP-43 in

frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science *314*, 130–

133.

40. Lin, Y.-L., Nhieu, J., Liu, P.-Y., Le, G., Lee, D.J., Wei, C.-W., Lin, Y.-W., Oh, S.-H.,

Lowe, D., and Wei, L.-N. (2022). CRABP1-CaMKII-Agrn regulates the maintenance of

neuromuscular junction in spinal motor neuron. Cell Death Differ. *29*, 1744–1756.

41. Cooper-Knock, J., Jenkins, T., and Shaw, P.J. (2013). Clinical and Molecular Aspects of

Motor Neuron Disease. Preprint,

https://doi.org/10.4199/c00093ed1v01y201309gmm004

https://doi.org/10.4199/c00093ed1v01y201309gmm004.

42. Lin, Y.-H., Dodd, J.E., Cutillo, L., Castelli, L.M., Mihaylov, S.R., Norris, K., Higginbottom,

A., Walsh, M.J., Cooper-Knock, J., Robin Highley, J., et al. (2024). GRASPS: a simple-

to-operate translatome technology reveals omics-hidden disease-associated pathways

in TDP-43-related amyotrophic lateral sclerosis. bioRxiv, 2024.03.04.583294.

https://doi.org/10.1101/2024.03.04.583294.

43. Schrøder, J.M., Larsen, J., Komarova, Y., Akhmanova, A., Thorsteinsson, R.I.,

Grigoriev, I., Manguso, R., Christensen, S.T., Pedersen, S.F., Geimer, S., et al. (2011).

EB1 and EB3 promote cilia biogenesis by several centrosome-related mechanisms. J

Cell Sci *124*, 2539–2551.

44. Zhang, Y., He, M., and Pan, J. (2025). Axonemal microtubule dynamics in the assembly

and disassembly of cilia. Biochem Soc Trans *53*. https://doi.org/10.1042/BST20240688.

45. Linares, G.R., Li, Y., Chang, W.H., Rubin-Sigler, J., Mendonca, S., Hong, S., Eoh, Y.,

Guo, W., Huang, Y.H., Chang, J., et al. (2023). SYF2 suppression mitigates

neurodegeneration in models of diverse forms of ALS. Cell Stem Cell *30*.

https://doi.org/10.1016/j.stem.2023.01.005.

46. Shaw, P.J., and Ince, P.G. (1997). Glutamate, excitotoxicity and amyotrophic lateral

sclerosis. J. Neurol. *244 Suppl 2*, S3–S14.

47. Van Den Bosch, L., Van Damme, P., Bogaert, E., and Robberecht, W. (2006). The role

of excitotoxicity in the pathogenesis of amyotrophic lateral sclerosis. Biochim. Biophys.

Acta *1762*, 1068–1082.

48. Bowles, K.R., Silva, M.C., Whitney, K., Bertucci, T., Berlind, J.E., Lai, J.D., Garza, J.C.,

Boles, N.C., Mahali, S., Strang, K.H., et al. (2021). ELAVL4, splicing, and glutamatergic

dysfunction precede neuron loss in MAPT mutation cerebral organoids. Cell *184*.

https://doi.org/10.1016/j.cell.2021.07.003.

49. Becker, L.A., Huang, B., Bieri, G., Ma, R., Knowles, D.A., Jafar-Nejad, P., Messing, J.,

Kim, H.J., Soriano, A., Auburger, G., et al. (2017). Therapeutic reduction of ataxin-2

extends lifespan and reduces pathology in TDP-43 mice. Nature *544*, 367–371.

50. Chen, K.M., Cofer, E.M., Zhou, J., and Troyanskaya, O.G. (2019). Selene: a PyTorch-

based deep learning library for sequence data. Nat. Methods *16*, 315–318.

51. Diekstra, F.P., van Vught, P.W.J., van Rheenen, W., Koppers, M., Pasterkamp, R.J.,

van Es, M.A., Schelhaas, H.J., de Visser, M., Robberecht, W., Van Damme, P., et al.

(2012). UNC13A is a modifier of survival in amyotrophic lateral sclerosis. Neurobiol.

Aging *33*, 630.e3–e8.

52. Miller, T.M., Cudkowicz, M.E., Genge, A., Shaw, P.J., Sobue, G., Bucelli, R.C., Chiò, A.,

Van Damme, P., Ludolph, A.C., Glass, J.D., et al. (2022). Trial of Antisense

Oligonucleotide Tofersen for SOD1 ALS. N. Engl. J. Med. *387*, 1099–1110.

53. Yamashita, S., Migita, A., Hayashi, K., Hirahara, T., Kimura, E., Maeda, Y., Hirano, T.,

and Uchino, M. (2010). Amyotrophic lateral sclerosis in a patient with Kartagener

syndrome. Amyotroph. Lateral Scler. *11*, 402–404.

54. De Decker, M., Zelina, P., Moens, T.G., Eggermont, K., Moisse, M., Veldink, J.H., Van

Den Bosch, L., Jeroen Pasterkamp, R., and Van Damme, P. (2022). C21orf2 mutations

found in ALS disrupt primary cilia function. bioRxiv, 2022.02.28.482239.

https://doi.org/10.1101/2022.02.28.482239.

55. van Rheenen, W., Shatunov, A., Dekker, A.M., McLaughlin, R.L., Diekstra, F.P., Pulit,

S.L., van der Spek, R.A.A., Võsa, U., de Jong, S., Robinson, M.R., et al. (2016).

Genome-wide association analyses identify new risk variants and the genetic

architecture of amyotrophic lateral sclerosis. Nat. Genet. *48*, 1043–1048.

56. Ishikawa, H., and Marshall, W.F. (2017). Intraflagellar transport and ciliary dynamics.

Cold Spring Harb. Perspect. Biol. *9*, a021998.

57. Lin, Y.-L., Lin, Y.-W., Nhieu, J., Zhang, X., and Wei, L.-N. (2020). Sonic hedgehog-Gli1

1329  signaling and cellular retinoic acid binding protein 1 gene regulation in motor neuron

1330  differentiation and diseases. Int. J. Mol. Sci. *21*, 4125.

1331 58. Brown, A.-L., Wilkins, O.G., Keuss, M.J., Hill, S.E., Zanovello, M., Lee, W.C., Bampton,

1332  A., Lee, F.C.Y., Masino, L., Qi, Y.A., et al. (2022). TDP-43 loss and ALS-risk SNPs drive

1333  mis-splicing and depletion of UNC13A. Nature *603*, 131–137.

1334 59. Ma, X.R., Prudencio, M., Koike, Y., Vatsavayai, S.C., Kim, G., Harbinski, F., Briner, A.,

1335  Rodriguez, C.M., Guo, C., Akiyama, T., et al. (2022). TDP-43 represses cryptic exon

1336  inclusion in the FTD–ALS gene UNC13A. Nature *603*, 124–130.

1337 60. Karczewski, K.J., Francioli, L.C., Tiao, G., Cummings, B.B., Alföldi, J., Wang, Q.,

1338  Collins, R.L., Laricchia, K.M., Ganna, A., Birnbaum, D.P., et al. (2020). The mutational

1339  constraint spectrum quantified from variation in 141,456 humans. Nature *581*, 434–443.

1340 61. Uhlén, M., Fagerberg, L., Hallström, B.M., Lindskog, C., Oksvold, P., Mardinoglu, A.,

1341  Sivertsson, Å., Kampf, C., Sjöstedt, E., Asplund, A., et al. (2015). Proteomics. Tissue-

1342  based map of the human proteome. Science *347*, 1260419.

1343 62. Yadav, A., Matson, K.J.E., Li, L., Hua, I., Petrescu, J., Kang, K., Alkaslasi, M.R., Lee,

1344  D.I., Hasan, S., Galuta, A., et al. (2023). A cellular taxonomy of the adult human spinal

1345  cord. Neuron *111*, 328–344.e7.

1346 63. Humphrey, J., Venkatesh, S., Hasan, R., Herb, J.T., de Paiva Lopes, K., Küçükali, F.,

1347  Byrska-Bishop, M., Evani, U.S., Narzisi, G., Fagegaltier, D., et al. (2023). Integrative

1348  transcriptomic analysis of the amyotrophic lateral sclerosis spinal cord implicates glial

1349  activation and suggests new risk genes. Nat. Neurosci. *26*, 150–162.

1350 64. Nguyen, D.-T., Mathias, S., Bologa, C., Brunak, S., Fernandez, N., Gaulton, A., Hersey,

1351  A., Holmes, J., Jensen, L.J., Karlsson, A., et al. (2017). Pharos: Collating protein

1352  information to shed light on the druggable genome. Nucleic Acids Res. *45*, D995–

1353  D1002.

1354 65. Kelleher, K.J., Sheils, T.K., Mathias, S.L., Yang, J.J., Metzger, V.T., Siramshetty, V.B.,

1355  Nguyen, D.-T., Jensen, L.J., Vidović, D., Schürer, S.C., et al. (2023). Pharos 2023: an

1356  integrated resource for the understudied human proteome. Nucleic Acids Res. *51*,

1357  D1405–D1416.

1358 66. Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O.,

1359  Tunyasuvunakool, K., Bates, R., Žídek, A., Potapenko, A., et al. (2021). Highly accurate

1360  protein structure prediction with AlphaFold. Nature *596*, 583–589.

1361 67. Krivák, R., and Hoksza, D. (2018). P2Rank: machine learning based tool for rapid and

1362  accurate prediction of ligand binding sites from protein structure. J. Cheminform. *10*, 39.

1363 68. Cedarbaum, J.M., Stambler, N., Malta, E., Fuller, C., Hilt, D., Thurmond, B., and

1364  Nakanishi, A. (1999). The ALSFRS-R: a revised ALS functional rating scale that

1365  incorporates assessments of respiratory function. J. Neurol. Sci. *169*, 13–21.

69. Proudfoot, M., Jones, A., Talbot, K., Al-Chalabi, A., and Turner, M.R. (2016). The
ALSFRS as an outcome measure in therapeutic trials and its relationship to symptom
onset. Amyotroph. Lateral Scler. Frontotemporal Degener. *17*, 414–425.
70. Bruse, N., and van Heeringen, S.J. (2018). GimmeMotifs: an analysis framework for
transcription factor motif analysis. bioRxiv, 474403. https://doi.org/10.1101/474403.
71. Szklarczyk, D., Kirsch, R., Koutrouli, M., Nastou, K., Mehryary, F., Hachilif, R., Gable,
A.L., Fang, T., Doncheva, N.T., Pyysalo, S., et al. (2023). The STRING database in
2023: protein-protein association networks and functional enrichment analyses for any
sequenced genome of interest. Nucleic Acids Res. *51*, D638–D646.
72. Krishnan, A., Zhang, R., Yao, V., Theesfeld, C.L., Wong, A.K., Tadych, A., Volfovsky,
N., Packer, A., Lash, A., and Troyanskaya, O.G. (2016). Genome-wide prediction and
functional characterization of the genetic basis of autism spectrum disorder. Nat.
Neurosci. *19*, 1454–1462.
73. Blondel, V.D., Guillaume, J.-L., Lambiotte, R., and Lefebvre, E. (2008). Fast unfolding of
communities in large networks. J. Stat. Mech. *2008*, P10008.
74. Wu, T., Hu, E., Xu, S., Chen, M., Guo, P., Dai, Z., Feng, T., Zhou, L., Tang, W., Zhan,
L., et al. (2021). clusterProfiler 4.0: A universal enrichment tool for interpreting omics
data. Innovations *2*. https://doi.org/10.1016/j.xinn.2021.100141.
75. Chen, E.Y., Tan, C.M., Kou, Y., Duan, Q., Wang, Z., Meirelles, G.V., Clark, N.R., and
Ma'ayan, A. (2013). Enrichr: interactive and collaborative HTML5 gene list enrichment
analysis tool. BMC Bioinformatics *14*, 1–14.
76. Project MinE ALS Sequencing Consortium (2018). Project MinE: study design and pilot
analyses of a large-scale whole-genome sequencing study in amyotrophic lateral
sclerosis. Eur. J. Hum. Genet. *26*, 1537–1546.
77. Brooks, B.R. (1994). El Escorial World Federation of Neurology criteria for the diagnosis
of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic
Lateral Sclerosis of the World Federation of Neurology Research Group on
Neuromuscular Diseases and the El Escorial "Clinical limits of amyotrophic lateral
sclerosis" workshop contributors. J. Neurol. Sci. *124 Suppl*, 96–107.
78. Bray, N.L., Pimentel, H., Melsted, P., and Pachter, L. (2016). Near-optimal probabilistic
RNA-seq quantification. Nat. Biotechnol. *34*, 525–527.
79. Robinson, M.D., and Oshlack, A. (2010). A scaling normalization method for differential
expression analysis of RNA-seq data. Genome Biol. *11*, R25.
80. Ludwik, K.A., Telugu, N., Schommer, S., Stachelscheid, H., and Diecke, S. (2023).
ASSURED-optimized CRISPR protocol for knockout/SNP knockin in hiPSCs. STAR
Protoc *4*, 102406.
81. Varcianna, A., Myszczynska, M.A., Castelli, L.M., O'Neill, B., Kim, Y., Talbot, J., Nyberg,

S., Nyamali, I., Heath, P.R., Stopford, M.J., et al. (2019). Micro-RNAs secreted through

astrocyte-derived extracellular vesicles cause neuronal network degeneration in

C9orf72 ALS. Preprint, https://doi.org/10.1016/j.ebiom.2018.11.067

https://doi.org/10.1016/j.ebiom.2018.11.067.

82. Castelli, L.M., Cutillo, L., Souza, C.D.S., Sanchez-Martinez, A., Granata, I., Lin, Y.-H.,

Myszczynska, M.A., Heath, P.R., Livesey, M.R., Ning, K., et al. (2021). SRSF1-

dependent inhibition of C9ORF72-repeat RNA nuclear export: genome-wide

mechanisms for neuroprotection in amyotrophic lateral sclerosis. Mol. Neurodegener.

16, 53.

83. Du, Z.-W., Chen, H., Liu, H., Lu, J., Qian, K., Huang, C.-L., Zhong, X., Fan, F., and

Zhang, S.-C. (2015). Generation and expansion of highly pure motor neuron progenitors

from human pluripotent stem cells. Nat. Commun. *6*, 6626.

84. Artyukhov, A.S., Dashinimaev, E.B., Tsvetkov, V.O., Bolshakov, A.P., Konovalova, E.V.,

Kolbaev, S.N., Vorotelyak, E.A., and Vasiliev, A.V. (2017). New genes for accurate

normalization of qRT-PCR results in study of iPS and iPS-derived cells. Gene *626*, 234–

240.

85. Tinevez, J.-Y., Perry, N., Schindelin, J., Hoopes, G.M., Reynolds, G.D., Laplantine, E.,

Bednarek, S.Y., Shorte, S.L., and Eliceiri, K.W. (2017). TrackMate: An open and

extensible platform for single-particle tracking. Methods *115*, 80–90.

86. Zdrazil, B., Felix, E., Hunter, F., Manners, E.J., Blackshaw, J., Corbett, S., de Veij, M.,

Ioannidis, H., Lopez, D.M., Mosquera, J.F., et al. (2024). The ChEMBL Database in

2023: a drug discovery platform spanning multiple bioactivity data types and time

periods. Nucleic Acids Res. *52*, D1180–D1192.

87. Kim, S., Chen, J., Cheng, T., Gindulyte, A., He, J., He, S., Li, Q., Shoemaker, B.A.,

Thiessen, P.A., Yu, B., et al. (2023). PubChem 2023 update. Nucleic Acids Res. *51*,

D1373–D1380.

88. UniProt Consortium (2023). UniProt: the Universal Protein Knowledgebase in 2023.

Nucleic Acids Res. *51*, D523–D531.

89. Varadi, M., Anyango, S., Deshpande, M., Nair, S., Natassia, C., Yordanova, G., Yuan,

D., Stroe, O., Wood, G., Laydon, A., et al. (2022). AlphaFold Protein Structure

Database: massively expanding the structural coverage of protein-sequence space with

high-accuracy models. Nucleic Acids Res. *50*, D439–D444.

1435

① Interpretation of MN noncoding variants

E-P links

ABC model

gene

ATAC-seq
H3K27ac ChIP-seq

TFs
CRE

RNA-seq
Hi-C

Variant effect

NeuroNet

Effect prediction

TTCCAAGCTAC
TTCCAGGCTAC

Functional variant

③ Survival analysis

fRV-based gene burden

Individuals

Cox model

26 covariates

Low risk
High risk

Survival
Time

② Whole-genome sequencing

project MinE
Make it yours

n = 6,715

ALS patients

Clinical information

• Sex
• Age at blood draw
• Age at onset
• Age at death
• C9orf72
• Site of onset
• etc

④ Experimental validation

CRISPR-Cas9

chr7:76,009,472:C>T

ALS phenotypes

CCDC146 expression

Isogenic Edited

MN degeneration

Cilia dysfunction

⑤ ASO suppression of *CCDC146 in vitro* & *in vivo*

ASO

CCDC146 ASO

RNAse H

mRNA degradation

C9, TARDBP, sporadic iNs
(n = 11)

TAR4/4 mouse
(n = 32)

Survival rescue

Ameliorated phenotypes

Rescued survival

CCDC146 ASO
NC ASO

Survival
Time

A

B

C

A

B

D

C

A

B

pLDDT

■ (90, 100)
■ (70, 90)
■ (50, 70)
■ (0, 50)

A

$P = 5.9 \times 10^{-3}$
$\beta = 0.85$

B

$P = 0.044$
$\beta = -0.79$
Difference in survival = 0.75

Low *ZNF839* expression
High *ZNF839* expression